



Author Index to CGC Volumes 86-92

- A
Abazis D, 86:65, 91:82
Abbondandolo A, 88:95
Abdelhay E, 86:183, 92:92
Abeliovich D, 86:1, 89:1
Abumrad NN, 90:63
Acín P, 86:162
Acosta Almeida MT, 91:71
Adair L, 87:55
Agapitos M, 90:157
Alberts DS, 87:55
Albatar M, 86:153
Alkat Al-Katib A, 86:143
Allan DJ, 91:77
Allen EF, 90:24
Alm P, 88:53
Alonso A, 88:49
Al Saadi A, 89:177
Amar A, 86:1
Ambra R, 87:112
Ambros PF, 87:161, 91:95
Ameys G, 88:86
Amiel A, 92:14
Anamthawat-Jónsson K, 88:1, 92:37
Andrade W, 87:4
Ansari MQ, 88:170
Antachopoulos C, 90:157
Antônio G, 88:90
Antonelli A, 87:112
Apiou F, 90:75
Apostolov P, 86:80
Arcuri C, 90:17
Arel-Kilic G, 89:77
Argyriou-Tirita A, 88:103
Arheden K, 89:88
Arkesteijn GJA, 88:69
Armstrong RF, 87:7
Arranz E, 87:1, 87:172
Ashihara E, 86:72
Asko-Seljavaara S, 86:170
Aslo A, 86:136
Athma P, 92:130
Atkin NB, 89:129, 92:87
Attuati V, 89:153
Auer G, 86:95
Augustus M, 89:82, 91:53
Ayan I, 89:77
Ayraud N, 89:175

B
BaĖovskiy J, 90:106
Badillo A, 90:142
Bae V, 87:14
Baert L, 87:79, 89:57
Baialardo EM, 87:75, 92:43
Bajalica-Lagerkrantz S, 90:102
Balboni M, 90:171
Balfour C, 87:55
Balsamo R, 90:171
Baranov AE, 87:182

Bardi A, 90:171
Barreiro C, 92:43
Barriga F, 87:4
Barril N, 91:74
Bartnitzke S, 86:39, 86:92, 87:148, 87:152, 90:88, 90:154
Bartsch O, 86:131
Basaran S, 89:77
Basso G, 91:13
Bastida P, 89:163
Batanian JR, 90:29
Bates SE, 92:99
Batsakis JG, 87:29, 89:38
Bauchinger M, 90:37
Bauer S, 91:95
Bayar E, 89:177
Beach B, 92:135
Becker K, 92:46
Bihal K, 90:106
Behm FG, 89:136
Belge G, 86:39
Bell JM, 90:1
Bellomo MJ, 89:44
Ben-Bassat I, 89:118
Benedict WF, 88:43
Benítez J, 87:1, 87:172
Ben-Neriah S, 86:1, 89:1
Bennett JM, 86:31
Benslimane A, 86:124
Bentz M, 87:107
Benye Ben-Yehuda D, 89:1
Bercowicz M, 89:118
Berger R, 86:76, 89:126
Bergerheim USR, 86:95
Bernard P, 87:82
Bernardes JE, 86:83
Bernstein J, 92:111
Bertin P, 87:4
Besses C, 86:162
Betti R, 87:88
Betts DR, 92:144
Betz J, 87:156, 88:155
Beverstock GC, 89:132
Bhat KR, 89:105
Bhat SM, 89:105
Bigoni R, 90:171
Biondi A, 89:153
Birch JM, 90:14
Birdsall SH, 87:90
Björkqvist A-M, 89:7
Blomqvist C, 86:170
Bocchini V, 90:17
Bogliolo M, 88:95
Bol S, 90:88
Bolcato S, 91:13
Bonassi S, 88:95
Bonatti S, 88:95
Bonduel M, 87:75
Bonk U, 86:92, 87:148, 87:152, 90:154

Bordessoule D, 87:82
Borkhardt A, 88:103
Borrego S, 88:90
Bosly A, 92:31
Boudousquie AC, 92:116
Bousfiha A, 86:124
Bržinová J, 86:131, 88:141
Branda RE, 90:24
Breitfeld PP, 92:111
Bridge JA, 88:49, 88:163, 89:49, 89:61, 91:8, 91:65, 92:150
Brigaudeau C, 87:82
Brok-Simoni F, 90:176
Brothman A, 87:14
Brown M, 88:118
Bruzze O, 89:44
Bruzzone E, 88:95
Bruzzone R, 89:31, 90:166
Bullerdiek J, 86:39, 86:92, 87:148, 87:152, 90:88, 90:154
Buño I, 86:18, 89:3

C
Campbell J, 87:167
Campbell MJ, 86:136
Campomenosi P, 88:95
Cano I, 90:118
Cao Q, 88:110
Capalash N, 88:30, 88:175
Carda-Batalla C, 90:57
Carrasco Juan JL, 91:71
Carriço KC, 92:92
Carvalho C, 89:34
Casalone R, 90:17
Casey G, 86:116
Cassiman J-J, 92:31
Castagné C, 89:44
Castañeda A, 90:118
Castoldi G, 86:120, 90:171, 92:31
Catovsky D, 86:89
Cavalli IJ, 89:21
Celli P, 91:13
Chaddock WM, 90:1
Chadli B, 86:124
Chaffee S, 86:150
Chan CH, 88:151
Chan LC, 88:92
Chan TK, 86:13, 89:74
Chan V, 86:13, 88:151, 89:74
Char DH, 90:95
Charrin C, 89:126
Chatelain B, 92:31
Chen D-S, 86:102
Chen H-L, 86:102
Chen P-M, 86:177
Chen S-J, 88:110
Chen TR, 90:91, 91:91
Chen Y-C, 86:102

Chen Z, 86:29, 88:110, 89:173, 90:184
Chen Z-H, 86:22
Chessa L, 87:112
Chiou T-J, 86:177
Chiu EKW, 89:74
Chou D, 88:136
Cigudosa JC, 91:71
Clarke MR, 86:107
Clayman GL, 87:29
Clément F, 89:44
Cobos E, 92:1, 92:50
Cohen I, 87:161
Cohen J, 89:173
Coll MD, 89:163
Collini P, 90:17
Collins VP, 86:95
Compean R, 86:143
Conti M, 87:11
Contis LC, 86:107
Cooley LD, 87:34
Cooper CS, 87:90
Cordero di Montezemolo L, 91:13
Corless CL, 92:116
Cornélio DA, 89:21
Coutinho J, 87:38
Cuneo A, 86:120, 90:171, 92:31
Currie JL, 87:167
Cyubachi A, 90:49

D
da Costa M, 88:167
Dal Cin P, 86:39, 86:58, 86:86, 87:79, 87:85, 87:176, 89:57, 89:181, 91:61, 92:31, 92:147
Dalance C, 92:150
Dan ME, 86:143
Dave BJ, 87:24, 92:66
De Angeli C, 86:120
Deboer J, 92:150
DeBoer JM, 91:8
De Busscher C, 89:77
De Conti OJ, 86:46
Defavery R, 86:83
de Groot N, 89:69
Deichert U, 87:148, 90:88
Delattre J-Y, 92:73
Della Coletta L, 88:144
Del Porto G, 90:132
del Senno L, 86:120
De Mattei M, 90:17
de Meijer PHEM, 89:132
Deneffe G, 89:181
Denis A, 92:85
Dennis TR, 87:41
den Ottolander GJ, 89:132
De Potter C, 90:86
De Paula MTM, 86:183



Author Index to CGC Volumes 86-92

- A
Abazis D, 86:65, 91:82
Abbondandolo A, 88:95
Abdelhay E, 86:183, 92:92
Abeliovich D, 86:1, 89:1
Abumrad NN, 90:63
Acín P, 86:162
Acosta Almeida MT, 91:71
Adair L, 87:55
Agapitos M, 90:157
Alberts DS, 87:55
Albitar M, 86:153
Alkat Al-Katib A, 86:143
Allan DJ, 91:77
Allen EF, 90:24
Alm P, 88:53
Alonso A, 88:49
Al Saadi A, 89:177
Amar A, 86:1
Ambra R, 87:112
Ambros PF, 87:161, 91:95
Ameys G, 88:86
Amiel A, 92:14
Anamthawat-Jónsson K, 88:1, 92:37
Andrade W, 87:4
Ansari MQ, 88:170
Antachopoulos C, 90:157
Antônio G, 88:90
Antonelli A, 87:112
Apiou F, 90:75
Apostolov P, 86:80
Arcuri C, 90:17
Arel-Kilic G, 89:77
Argyriou-Tirita A, 88:103
Arheden K, 89:88
Arkesteyn GJA, 88:69
Armstrong RF, 87:7
Arranz E, 87:1, 87:172
Ashihara E, 86:72
Asko-Seljavaara S, 86:170
Aslo A, 86:136
Athma P, 92:130
Atkin NB, 89:129, 92:87
Attuati V, 89:153
Auer G, 86:95
Augustus M, 89:82, 91:53
Ayan I, 89:77
Ayraud N, 89:175

B
BaĖovskiy J, 90:106
Badillo A, 90:142
Bae V, 87:14
Baert L, 87:79, 89:57
Baialardo EM, 87:75, 92:43
Bajalica-Lagerkrantz S, 90:102
Balboni M, 90:171
Balfour C, 87:55
Balsamo R, 90:171
Baranov AE, 87:182

Bardi A, 90:171
Barreiro C, 92:43
Barriga F, 87:4
Barril N, 91:74
Bartnitzke S, 86:39, 86:92, 87:148, 87:152, 90:88, 90:154
Bartsch O, 86:131
Basaran S, 89:77
Basso G, 91:13
Bastida P, 89:163
Batanian JR, 90:29
Bates SE, 92:99
Batsakis JG, 87:29, 89:38
Bauchinger M, 90:37
Bauer S, 91:95
Bayar E, 89:177
Beach B, 92:135
Becker K, 92:46
Bihal K, 90:106
Behm FG, 89:136
Belge G, 86:39
Bell JM, 90:1
Bellomo MJ, 89:44
Ben-Bassat I, 89:118
Benedict WF, 88:43
Benítez J, 87:1, 87:172
Ben-Neriah S, 86:1, 89:1
Bennett JM, 86:31
Benslimane A, 86:124
Bentz M, 87:107
Benye Ben-Yehuda D, 89:1
Bercowicz M, 89:118
Berger R, 86:76, 89:126
Bergerheim USR, 86:95
Bernard P, 87:82
Bernardes JE, 86:83
Bernstein J, 92:111
Bertin P, 87:4
Besses C, 86:162
Betti R, 87:88
Betts DR, 92:144
Betz J, 87:156, 88:155
Beverstock GC, 89:132
Bhat KR, 89:105
Bhat SM, 89:105
Bigoni R, 90:171
Biondi A, 89:153
Birch JM, 90:14
Birdsall SH, 87:90
Björkqvist A-M, 89:7
Blomqvist C, 86:170
Bocchini V, 90:17
Bogliolo M, 88:95
Bol S, 90:88
Bolcato S, 91:13
Bonassi S, 88:95
Bonatti S, 88:95
Bonduel M, 87:75
Bonk U, 86:92, 87:148, 87:152, 90:154

Bordessoule D, 87:82
Borkhardt A, 88:103
Borrego S, 88:90
Bosly A, 92:31
Boudousquie AC, 92:116
Bousfiha A, 86:124
Bržínová J, 86:131, 88:141
Branda RE, 90:24
Breitfeld PP, 92:111
Bridge JA, 88:49, 88:163, 89:49, 89:61, 91:8, 91:65, 92:150
Brigaudeau C, 87:82
Brok-Simoni F, 90:176
Brothman A, 87:14
Brown M, 88:118
Bruzze O, 89:44
Bruzzone E, 88:95
Bruzzone R, 89:31, 90:166
Bullerdiek J, 86:39, 86:92, 87:148, 87:152, 90:88, 90:154
Buño I, 86:18, 89:3

C
Campbell J, 87:167
Campbell MJ, 86:136
Campomenosi P, 88:95
Cano I, 90:118
Cao Q, 88:110
Capalash N, 88:30, 88:175
Carda-Batalla C, 90:57
Carrasco Juan JL, 91:71
Carriço KC, 92:92
Carvalho C, 89:34
Casalone R, 90:17
Casey G, 86:116
Cassiman J-J, 92:31
Castagné C, 89:44
Castañeda A, 90:118
Castoldi G, 86:120, 90:171, 92:31
Catovsky D, 86:89
Cavalli IJ, 89:21
Celli P, 91:13
Chaddock WM, 90:1
Chadli B, 86:124
Chaffee S, 86:150
Chan CH, 88:151
Chan LC, 88:92
Chan TK, 86:13, 89:74
Chan V, 86:13, 88:151, 89:74
Char DH, 90:95
Charrin C, 89:126
Chatelain B, 92:31
Chen D-S, 86:102
Chen H-L, 86:102
Chen P-M, 86:177
Chen S-J, 88:110
Chen TR, 90:91, 91:91
Chen Y-C, 86:102

Chen Z, 86:29, 88:110, 89:173, 90:184
Chen Z-H, 86:22
Chessa L, 87:112
Chiou T-J, 86:177
Chiu EKW, 89:74
Chou D, 88:136
Cigudosa JC, 91:71
Clarke MR, 86:107
Clayman GL, 87:29
Clément F, 89:44
Cobos E, 92:1, 92:50
Cohen I, 87:161
Cohen J, 89:173
Coll MD, 89:163
Collini P, 90:17
Collins VP, 86:95
Compean R, 86:143
Conti M, 87:11
Contis LC, 86:107
Cooley LD, 87:34
Cooper CS, 87:90
Cordero di Montezemolo L, 91:13
Corless CL, 92:116
Cornélio DA, 89:21
Coutinho J, 87:38
Cuneo A, 86:120, 90:171, 92:31
Currie JL, 87:167
Cyubachi A, 90:49

D
da Costa M, 88:167
Dal Cin P, 86:39, 86:58, 86:86, 87:79, 87:85, 87:176, 89:57, 89:181, 91:61, 92:31, 92:147
Dalance C, 92:150
Dan ME, 86:143
Dave BJ, 87:24, 92:66
De Angeli C, 86:120
Deboer J, 92:150
DeBoer JM, 91:8
De Busscher C, 89:77
De Conti OJ, 86:46
Defavery R, 86:83
de Groot N, 89:69
Deichert U, 87:148, 90:88
Delattre J-Y, 92:73
Della Coletta L, 88:144
Del Porto G, 90:132
del Senno L, 86:120
De Mattei M, 90:17
de Meijer PHEM, 89:132
Deneffe G, 89:181
Denis A, 92:85
Dennis TR, 87:41
den Ottolander GJ, 89:132
De Potter C, 90:86
De Paula MTM, 86:183

- de Ruiter AJ, 86:147
 Dervenoulas J, 90:182
 De Smet L, 87:85
 De Souza J, 86:183
 De Souza MHO, 92:92
 De Souza Fernandez T, 86:183
 Devi S, 89:105
 Dewald GW, 92:54
 De Wever I, 86:58, 92:147
 De Wolf-Peters C, 89:181
 Dhar PK, 89:105
 Dhillon IK, 86:54
 Dhillon VS, 86:54
 Di Benedetto J Jr, 89:157
 Díez-Martín JL, 89:141
 Dierlamm J, 88:86, 89:109, 92:31
 Dijkhuizen T, 92:141
 Dimitroulakis J, 92:58
 Döhner H, 87:107, 89:153
 Doco-Fenzy M, 90:63
 Dong S, 88:110
 Donti E, 91:40
 dos Anjos Teixeira M, 87:38
 Dossu JR, 92:4
 Dougherty S, 87:133
 Drożyńska E, 92:85
 Druck T, 88:136
 Duarte MHO, 86:83
 Dunn DM, 92:50
 Dunphy CH, 90:29
 Dutrillaux B, 90:75, 92:11
- E
 Edelman W, 87:14
 Egozcue J, 89:163
 Ehninger G, 90:33
 Elgamal AA, 87:79
 Elis A, 92:14
 Elizalde A, 90:142
 Elli R, 87:112
 El-Naggar AK, 87:29, 89:38
 Elomaa I, 86:170
 Emerson J, 87:55
 Emoto G, 90:80, 91:40
 Enomoto K, 90:49
 Erpelinck SLA, 88:69
 Escudero A, 87:172
 Evans DGR, 90:14
 Eyfjörd JE, 88:1, 92:37
- F
 Faa C, 88:158
 Fairweather RB, 89:52
 Falk RE, 86:165
 Fan FS, 86:177
 Fan Y-S, 87:7
 Favre B, 87:185
 Feder M, 89:120
 Feigin M, 92:14
 Felgner J, 87:52
 Felice MS, 92:43
 Feliu A, 87:75
 Ferguson HL, 87:34
 Fernández JL, 86:18, 89:141
 Fernández MN, 89:141
 Ferrant A, 88:86, 92:31
 Ferro MT, 92:79
 Ferti A, 90:182
 Fidler IJ, 92:58
 Filatov LV, 89:136
 Fink F-M, 91:95
- Finklestein JZ, 87:71
 Fioritoni G, 91:40
 Fischer K, 87:107
 Fitzgerald PH, 86:8
 Fleischman EW, 87:182
 Flesh M, 87:185
 Fletcher C, 92:147
 Fletcher CDM, 86:58
 Fletcher JA, 86:168
 Flexor M, 86:76
 Florensa L, 86:162
 Foidart J-M, 90:63
 Ford J, 86:116
 Fox M, 91:28
 Franken-Postma E, 86:156
 Franzén B, 86:95
 Frenkel MA, 87:182
 Fronza G, 88:95
 Fryns J-P, 89:181
 Fuerst MM, 86:165
 Fugazza G, 89:31, 90:166
 Fujimura T, 86:61
 Fujita N, 86:72
 Fujita S, 90:146
- G
 Gadner H, 91:95
 Gagos S, 90:157
 Gale G, 90:29
 Gallego J, 87:1
 Gallego MS, 87:75, 92:43
 Gan SU, 87:103
 Ganapathi R, 86:116
 Gandini D, 86:120
 Garcia JL, 86:86, 92:147
 García Miranda JL, 91:71
 Garcia-Palazzo IE, 89:92
 García-Sagredo JM, 92:79
 García Talavera J, 91:71
 Gardiner A, 92:24
 Garwicz S, 88:133
 Gentile SL, 88:95
 Georgiev G, 91:68
 Geurts van Kessel A, 87:95, 88:83, 89:146
 Geym M, 87:112
 Ghassemi A, 87:148
 Ghazvini S, 90:95
 Giles FJ, 86:165
 Gill SE, 87:90
 Gilles C, 90:63
 Gipsch N, 90:176
 Giudici G, 89:153
 Glasser L, 89:157
 Glassman AB, 86:153, 88:80
 Glassman ML, 89:69
 Gobuzov R, 87:161
 Gogineni SK, 88:167, 90:142
 Gonzalez GJR, 92:82
 González M, 86:86
 Gordeeva AA, 87:182
 Gosálvez J, 86:18, 89:141
 Goto H, 86:72
 Governatori M, 90:132
 Goyanes V, 86:18
 Grabowski D, 86:116
 Grammatico P, 90:132
 Granata P, 90:17
 Grebe G, 87:4
 Griffin CA, 87:167, 88:126
 Grigori-Romero MA, 92:28
 Grimaldi Oliveira PR, 91:74
 Gu L-j, 88:110
- Guan X-Y, 87:55
 Gudi R, 90:142
 Guo Y, 92:18
 Gupta BD, 88:175
 Gustafson E, 89:173
 Gusterson BA, 87:90, 87:179
 Gutierrez M, 87:75
 Gyárfás J, 91:88
- H
 Haas OA, 88:103
 Hagemeyer A, 86:156, 88:69
 Hagen J, 89:61
 Hagenbeek A, 88:69
 Hagermeijer A, 90:109
 Han K, 92:122
 Han X, 91:28
 Hanson CA, 92:54
 Hara T, 89:98
 Harif M, 86:124
 Harker Rhodes C, 86:150, 92:4
 Harris CC, 92:99
 Hashimi M, 87:156
 Hashimoto E, 86:185
 Hashimoto K, 88:26, 89:166, 90:49
 Hatake K, 90:45
 Hatakeyama N, 86:185
 Hatano Y, 88:26
 Hattinger C, 87:161
 Havlioglu N, 90:29
 Hawkins AL, 88:126
 Hawkins EP, 87:34
 Hayashi S, 89:98
 Hayes KJ, 86:153, 88:80
 Hda N, 86:124
 Hedges L, 88:35
 Hedges LK, 86:50
 Hedrick L, 87:167
 Heerema NA, 92:111
 Heim S, 88:53, 88:133, 92:95
 Heinonen K, 87:123
 Hennig Y, 87:148
 Hernández JM, 86:86, 92:147
 Hernández-Navarro H, 90:118
 Hernández Nieto L, 91:71
 Herrmann ME, 89:14, 90:70
 Heyderman E, 91:28
 Hikiji K, 89:85
 Hilliker C, 86:58
 Hinckley J, 88:66
 Hiorns LR, 86:89
 Hirai H, 86:72
 Hirose S, 90:49
 Hochberg A, 89:69
 Hoekstra HJ, 86:147, 92:141
 Hoeltge G, 86:116
 Hoffner L, 88:17
 Höfler H, 90:37
 Hölig K, 90:33
 Hopwood VL, 87:24
 Horák ID, 86:131
 Horstmann M, 88:103
 Hossfeld DK, 87:52, 89:109, 92:31
 Hsieh R-K, 86:177
 Hsu TC, 87:127
 Huang Q-H, 88:110
 Huang W, 88:110
 Huebner K, 88:136
 Huffermann K, 89:175
- Hughson MD, 87:133, 89:65
 Huh YO, 86:153
 Huysmans C, 86:39
- I
 Iannone R, 88:95
 Ide SE, 92:46
 Iliopoulos D, 90:157
 Illmer T, 90:33
 Imagawa S, 90:45
 Imielinski B, 92:85
 Inaba T, 86:72
 Indrák K, 90:106
 Inga A, 88:95
 Iosif CS, 92:95
 Iosif SC, 88:53
 Ireland CM, 87:112
 Isayama T, 91:40
 Ishiguro M, 90:80, 91:40
 Ito H, 89:114
 Iwama H, 86:61
 Iwasaki H, 90:80, 91:46
 Izumi T, 90:45
 Izzycka E, 92:85
- J
 Jackson Z, 89:129, 92:87
 Jackson-Cook C, 87:14
 Jacobson SH, 86:95
 Jaroková M, 90:106
 Jassem J, 92:85
 Jeffrey B, 92:150
 Jeison M, 87:161
 Jelínek J, 86:131
 Jia Y, 89:184
 Johansson B, 88:133, 92:8
 Johansson SL, 88:163, 89:49
 Jolly PC, 89:173
 Jonveaux P, 87:52, 89:126
 Joseph A, 89:105
 Josip K, 88:57
 Justica B, 87:38
- K
 Kabisch H, 88:103
 Kadam P, 86:181
 Kallioniemi O-P, 89:7
 Kamada N, 90:179
 Kamal NR, 92:54
 Kaneko S, 86:69
 Kaneko Y, 90:80, 91:40
 Kang CS, 92:122
 Kapaun P, 88:103
 Kapelushnik Y, 89:1
 Karayannakos P, 90:157
 Karhu R, 89:7
 Kastelan M, 88:57
 Kastury K, 88:136
 Katsura K, 90:146
 Kawachi Y, 89:85
 Kawakubo K, 86:61
 Kawamata N, 86:136
 Kenny-Moynihan MB, 89:61
 Kerler R, 87:140
 Keung Y-K, 92:1, 92:50
 Khalily M, 86:181
 Kikuchi M, 90:80, 91:40
 Kikuta T, 86:72
 Killary AM, 87:29, 89:38
 Kim BK, 92:122
 Kim SM, 92:122
 Kim WI, 92:122
 Kim YG, 92:122

- Kim YS, 92:122
 Kitamura H, 86:69
 Kivipensas P, 89:7
 Klein G, 86:95
 Klein-Szanto AJP, 89:120
 Kler RS, 86:54
 Knuutila S, 86:170, 89:7
 Köhler M, 88:133
 Kobayashi Y, 88:26
 Kodama A, 86:61, 89:114
 Koeffler HP, 86:136
 Kondo K, 86:69
 Konstantinova LN, 87:182
 Konstantopoulos K, 86:65
 Kontopidou F, 91:82
 Kools P, 86:39
 Kools PFF, 91:1
 Kopacz A, 91:37
 Kopelovich L, 90:125
 Kostakis A, 90:157
 Kovar H, 87:161
 Kreczy A, 91:95
 Kriæan P, 91:88
 Kröger N, 89:109
 Kroll S, 90:95
 Kroschinsky F, 90:33
 Kuang S-q, 86:110
 Kubonishi I, 86:185, 91:104
 Kubota T, 91:104
 Kubota Y, 88:181
 Kulagina OE, 87:182
 Kumar MR, 89:105
 Kumari U, 89:105
 Kume M, 88:26
 Kurczynski TW, 89:177
 Kuriki K, 90:45
 Kuriyama Y, 86:61
 Kusuanco DA, 86:165
 Kuzume T, 86:185
 Kwong KW, 88:92
 Kwong YL, 86:13, 88:151, 89:74, 90:93
- L
 Labella T, 87:103
 Lacour JP, 89:175
 Lalley PA, 90:63
 Lampkin BC, 86:136
 Lang CH, 90:63
 Lanza F, 86:120
 Larsen C-J, 86:76
 Latorraca A, 86:120
 Latour D, 88:118
 Laureys G, 90:86
 Lauwers GY, 90:184
 Lawce HJ, 92:116
 Lawrence GN, 86:165
 Lechner JF, 92:99
 Le Coniat M, 86:76
 Lee ACW, 88:92
 Lee KY, 92:122
 Legües E, 87:4
 Lehman TA, 92:99
 Leibundgut KE, 92:144
 Lemeiz P, 86:131
 Lemieux N, 90:80
 Lerer I, 86:1
 Leszl A, 91:13
 Leung S, 88:80
 Levin M, 87:11
 Li C, 86:95
 Li J, 92:18
 Li YS, 87:7
- Liang R, 86:13
 Liang RHS, 89:74
 Libouton J-M, 88:86
 Lichter P, 87:107
 Lillington DM, 87:48
 Lillo-Gil R, 92:90
 Lim SW, 86:165
 Lima M, 87:38
 Limon J, 89:88, 91:37, 92:85
 Lindgren V, 89:93
 Linnainmaa K, 89:7
 Lion T, 91:95
 Liozon E, 87:82
 Lipkin M, 90:125
 Lishner M, 92:14
 Lister TA, 87:48
 Litwin S, 89:120
 Liu J-H, 86:177
 Liu Y, 87:55
 Liu Z, 92:18
 Liu ZM, 89:92
 Llamas P, 89:141
 Lombart-Bosch A, 90:57, 92:28
 Lombardo A, 90:132
 Looijenga LHJ, 87:95, 89:146
 Look RM, 86:165
 López JL, 87:172
 López R, 90:118
 López-Fernández C, 86:18, 89:141
 López-Ginés C, 90:57
 López-Terrada L, 90:57
 López-Yarto A, 92:79
 Louis DN, 88:136
 Loukopoulos D, 86:65, 91:82
 Louwagie A, 88:86
 Lovell M, 87:29, 89:38
 Lowichik A, 88:170
 Lunde JH, 90:24
 Lynch EF, 86:107
 Lynch HT, 90:125
- M
 Maben KD, 92:111
 Macera MJ, 90:142
 Madahar CJ, 87:11
 Mageniz RE, 92:116
 Mahlamäki E, 87:123
 Malfoy B, 90:75
 Malheiro MI, 87:38
 Mandahl N, 89:88, 92:90
 Mandel M, 90:176
 Manneborg-Sandlund A, 86:95
 Manolova Y, 86:80, 91:68
 Manor Y, 92:14
 Mantzourani M, 91:82
 Mao X, 89:184
 Marchuk DA, 87:41
 Marcucci L, 87:112
 Mark HFL, 86:87, 87:92, 89:157
 Marras S, 88:158
 Martens ACHM, 88:69
 Martens F, 92:90
 Martiat P, 89:109
 Martin-Recio A, 90:118
 Martínez B, 87:1, 87:172
 Martinez J, 90:118
 Martini F, 90:17
 Martins C, 89:34
 Marynen P, 91:61
- Massey K, 87:55
 Mattson K, 89:7
 Mayayo M, 92:79
 McComb EN, 88:163, 91:8
 McComb RD, 91:8
 McConnell TS, 92:50
 McEntire BB, 88:144
 McGown G, 90:14
 McIntosh DG, 89:61
 McKeever PE, 87:41
 McManus AP, 87:179
 McNally R, 90:24
 Mecucci C, 86:35, 88:86, 89:109
 Medda C, 88:158
 Meese E, 90:63
 Meeus P, 88:86
 Méhes K, 86:129
 Meister P, 87:148
 Meletis J, 86:65
 Meloni A, 87:133
 Meloni AM, 88:155, 89:65, 90:184, 92:150
 Meltzer PS, 87:41
 Menichini P, 88:95
 Menke-Pluyers MBE, 90:109
 Mertens F, 89:88, 92:8, 92:90
 Michali E, 86:65
 Michalová K, 86:131, 88:141
 Michaux J-L, 86:35, 92:31
 Michaux L, 86:35, 88:86, 89:109
 Miharu N, 89:98
 Miyoshi I, 91:104
 Miki T, 90:49
 Miller CW, 86:136
 Miller JP, 88:39
 Miller-Canfield P, 86:181
 Milunsky A, 89:170
 Milunsky JM, 89:170
 Min T, 87:179, 91:40
 Minelli E, 90:17
 Mitelman F, 88:53, 88:133, 89:88, 92:8, 92:90, 92:95
 Mitev L, 86:80, 91:68
 Miura A, 90:49
 Miura AB, 88:26, 89:166
 Miura I, 88:26, 89:166, 90:49
 Miura Y, 90:45
 Miyamoto H, 88:181
 Miyashita T, 88:136
 Miyoshi I, 86:185, 91:104
 Mizobuchi H, 90:54
 Moerman P, 91:61
 Mohamed AN, 86:143
 Mohr B, 90:33
 Mohrenweiser HW, 88:136
 Molenaar WM, 86:147, 92:141
 Moll UM, 90:63
 Mollevanger P, 89:132
 Monk AJ, 88:76
 Montaldi A, 91:13
 Moore SK, 90:125
 Moos M, 87:107
 Mor C, 87:161
 Morandi P, 89:153
 Mordenti C, 90:132
 Morell-Quadreny L, 92:28
 Moretti S, 86:120
 Morgan D, 92:1
 Morgan DL, 92:50
 Morgan R, 86:29, 87:156, 89:173
- Morishita N, 91:104
 Morizio E, 91:40
 Morizot DC, 88:144
 Moro F, 88:95
 Morris CM, 86:8
 Mostafavi HS, 86:29
 Mostert MMC, 87:95, 89:146
 Mould S, 92:24
 Mrózek K, 91:37
 Mugneret F, 87:185
 Mühlematter D, 89:44
 Mulder AH, 90:109
 Muleris M, 92:11
 Müller P, 88:8
 Muneishi H, 86:185
 Muñoz R, 92:79
 Murakami K, 91:104
 Muroi K, 90:45
 Musilová J, 88:141
 Musio A, 88:184
- N
 Nagashima Y, 86:69
 Nagler A, 86:1
 Nairn RS, 88:144
 Nakagawa M, 86:72
 Nakai S, 90:146
 Nakamura H, 89:114
 Nakić M, 88:57
 Nayak S, 89:105
 Naylor SL, 92:46
 Nedoszytko B, 91:37
 Neelon R, 86:116
 Neff JR, 88:49, 88:163, 89:49, 91:8, 92:150
 Neiman RS, 92:111
 Nelson M, 88:49, 88:163
 Nelson MA, 87:55
 Neumann Y, 90:176
 Niggli FK, 92:144
 Nimura T, 88:26, 89:166, 90:49
 Nishihara T, 89:85
 Noël JC, 86:174
 Noll WW, 86:150
 Nolte I, 90:154
 Nordenskjöld M, 90:102
 Notohamiprodjo M, 92:82
 Nowak R, 90:33
- O
 Oelschlägel U, 90:33
 Ogata K, 90:80
 Ogawa Y, 90:45
 Ögmundsdóttir HM, 88:1, 92:37
 Oguma N, 90:179
 Ogur G, 89:77
 Oh EJ, 92:122
 Ohama K, 89:98
 Ohjimi Y, 90:80, 91:40
 Ohnuki Y, 92:99
 Ohshima A, 88:26, 89:166, 90:49
 Ohtsuki T, 90:45
 Ohtsuki Y, 90:54
 Ohya K-I, 90:45
 Ohyashiki JH, 86:61
 Ohyashiki K, 86:61, 89:114
 Okamoto E, 89:98
 Olde Weghuis D, 87:95, 89:146
 Oliveira P, 89:34
 Olson S, 92:116
 Oosterhuis JW, 87:95, 89:146

Or R, 86:1
Ortega JJ, 89:163
Oscier DG, 92:24
Otero Gómez A, 91:71
Ottaggio L, 88:95
Ozbek U, 89:77

P
Paaz U, 90:33
Paietta E, 86:31
Palazzo JP, 89:92
Palka G, 91:40
Pan Y, 92:18
Panani A, 90:182
Pangalis GA, 91:82
Pangalos C, 91:82
Pangalos K, 86:65
Park JP, 86:150, 89:52, 92:4
Parkin CA, 88:76
Parrington JM, 91:28
Parshad R, 88:43
Pasquini R, 89:21
Pathak S, 87:24, 92:58
Pauwels P, 87:176
Pedetour F, 89:175
Peila R, 91:40
Pejovic T, 88:53, 92:95
Pelín K, 89:7
Pellegata NS, 88:95
Peres LC, 86:83
Pérez-Losada A, 86:162
Pérez-Piñó T, 90:118
Perilongo G, 91:13
Perrin C, 89:175
Petković I, 88:57
Petrella T, 87:185
Petrinelli P, 87:112
Petrov A, 91:68
Pétursdóttir I, 88:1, 92:37
Pickering D, 92:150
Pienkowska M, 92:58
Piette J, 90:63
Pinilla J, 90:118
Pinkel D, 90:95
Pinkerton CR, 87:179
Pinto A, 90:130
Pisani R, 88:95
Pittman SM, 87:112
Piva N, 90:171
Plata E, 86:65
Plavšić N, 92:58
Ploton D, 90:63
Poisson M, 92:73
Polo N, 89:141
Polymeropoulos MH, 92:46
Porter S, 87:48
Porto B, 87:38
Poscente M, 90:132
Powles R, 91:40
Praloran V, 87:82
Preisler H, 86:181
Presti JC Jr, 88:66
Price FM, 88:43
Prieto J, 88:90
Pruitt JFM, 89:132
Puppo L, 90:166

Q
Qi H, 87:79, 92:147
Quevedo E, 90:118

R
Raani P, 89:118

Rabes HM, 87:140
Radl J, 86:156
Raimondi SC, 89:136
Rambaldi A, 89:153
Rangaratnam S, 92:73
Ranzani GN, 88:95
Rao TR, 89:105
Rao UNM, 88:17
Rappaport R, 92:130
Raptis SA, 90:182
Ravarino A, 88:158
Raymakers R, 88:83
Rechavi G, 90:176
Reddel RR, 92:99
Reed JC, 88:136
Reimann N, 90:154
Renshaw AA, 86:168
Resino M, 92:79
Reuter VE, 88:66
Ribeiro ACP, 87:38
Ribeiro EMSF, 89:21
Ribeiro RC, 92:92
Richkind KE, 87:71
Richman B, 89:61
Riede I, 90:135
Riethmüller G, 88:8
Rigolin GM, 90:171
Risueño C, 87:4
Rivas C, 87:1
Rivera GK, 89:136
Robens E, 90:37
Robert MG, 90:171
Roberts CA, 88:49
Robinson MG, 89:177
Robledo M, 87:1, 87:172
Rodrigues M, 87:38
Rodriguez A, 90:118
Rodriguez JM, 89:21
Rohen C, 86:92, 87:152
Roland B, 90:130
Roloson GJ, 88:39, 90:1
Román A, 87:1
Romansky SG, 87:71
Rombos J, 86:65
Roque L, 89:34
Rosner E, 89:118, 90:176
Rossi J, 92:43
Roszkiewicz A, 91:37, 92:85
Rotmensch J, 89:93
Rouleau GA, 92:73
Rowe D, 89:27
Roy J, 87:11
Rutledge MH, 92:73
Rydstedt LL, 90:63

S
Sainati L, 91:13
Saito K, 88:26, 90:45
Saito M, 88:26, 89:136, 89:166
Saitoh M, 90:49
Sakai N, 86:69
Salmon SE, 88:186
Samarokos M, 86:65
Samura O, 89:98
Sandberg AA, 86:29, 87:133, 87:156, 88:155, 89:65, 89:173, 90:184, 92:150
Sanford KK, 88:43
San Miguel JF, 86:86
San Roman C, 92:79
Sans-Sabrafen J, 86:162
Sariban E, 89:77
Sarrazin J, 92:73

Satge D, 87:63
Saunders AL, 90:184
Savarese TM, 86:22
Sawyer JR, 88:39, 90:1
Sbrana I, 88:184
Scheiff J-M, 86:35
Scheiner M, 88:35
Schlimok G, 88:8
Schmid ATL, 89:21
Schmidt PM, 89:44
Schneider NR, 88:170
Schoenmakers E, 86:39
Scholl C, 87:107
Schuler U, 90:33
Schwartz HS, 86:50, 88:35
Sciadini M, 86:50
Sciot R, 86:58, 87:85, 87:176, 92:147
Scrideli CA, 86:83
Sćudla V, 90:106
Secco C, 86:31
Seeger D, 87:52, 89:109
Seemayer TA, 88:49
Sehgal S, 88:175
Semenza JC, 92:135
Sengun Z, 89:77
Serpa A, 89:34
Sessarego M, 89:31, 90:166
Seto M, 88:26
Setsu K, 89:85
Shao J, 92:135
Sharma P, 88:175
Shekhter-Levin S, 86:107
Sherer ME, 86:107
Sherman R, 92:116
Shevlin DH, 86:29
Shigeta C, 90:179
Shim SI, 92:122
Shimamoto T, 86:61
Shimazaki C, 86:72
Shimizu K, 90:54
Shiozaki H, 88:181
Shipley JM, 87:90, 87:179
Shirota T, 89:114
Shreemati Y, 89:105
Shuin T, 86:69, 88:181
Sidaner I, 87:185
Silva FG, 87:133, 89:65
Silva MLM, 86:183, 92:92
Silvestro L, 91:13
Simões FV, 92:92
Simon MP, 89:175
Simonart T, 86:174
Singh R, 92:58
Skalkas G, 90:157
Smith MR, 86:143
Smith MT, 92:135
Smith NM, 88:76
Smith SR, 89:27
Soares FA, 86:83
Soares J, 89:34
Sobti RC, 88:30, 88:175
Söderhäll M, 86:95
Solé F, 86:162
Sonobe H, 90:54
Sørensen A-G, 90:102
Soušková I, 90:106
Speleman F, 90:86
Sperandio-Roxo VMM, 89:21
Spitz MR, 87:24
Squire JA, 92:58
Staats B, 87:152
Stamatopoulos K, 91:82

Stamps AC, 87:90
Stark B, 87:161
Steele P, 86:181
Steele SJ, 91:28
Steinarsdóttir M, 88:1, 92:37
Stella M, 91:13
Stellink F, 88:83
Stenman G, 86:39
Stoba C, 92:85
Stock C, 91:95
Stoepker MEJ, 86:147
Stone JF, 86:29, 89:173
Strehl S, 91:95
Stul M, 92:31
Stuppia L, 91:40
Su X-Y, 88:110
Sudo Y, 86:72
Sugihara H, 90:146
Suijkerbuijk RF, 89:146
Sumikuma T, 86:72
Sundareshan TS, 89:82, 91:53
Surti U, 88:17
Swansbury GJ, 86:89, 87:179
Swansbury JG, 91:40
Swarts S, 91:65
Swarts SJ, 89:49
Swierblewski M, 91:37
Swift M, 92:130
Szűcs S, 90:37
Szymanska J, 86:170

T
Tabak DG, 92:92
Taetle R, 87:55
Taguchi H, 91:104
Taguchi T, 89:92, 89:120
Tajara EH, 91:74
Takahashi N, 88:26, 89:166, 90:49
Talpos GB, 90:63
Tammilehto L, 89:7
Tang I, 92:14
Tarkkanen M, 86:170
Tarone RE, 88:43
Tashiro H, 90:80
ten Bokkel Huinink D, 89:132
Teo C, 90:1
Testa JR, 89:92, 89:120
Thein ATA, 91:28
Thode B, 87:148, 90:88
Thomas JR, 90:1
Thompson FH, 87:55
Thornicroft M, 90:14
Thorne P, 92:58
Tigaud I, 89:126
Tilanus HW, 90:109
Timmons CF, 88:170
Tingaard Pedersen N, 90:102
Toda M, 90:54
Tognon M, 90:17
Tokutake AS, 89:21
Tone LG, 86:83
Tonk V, 88:170, 92:1, 92:50
Toren A, 90:176
Torres FM, 86:83
Tosi S, 89:153
Toyama K, 86:61, 89:114
Trachli A, 86:124
Trakhtenbrot L, 90:176
Trent JM, 87:41, 87:55, 88:186
Tricker K, 90:14
Trimoreau F, 87:82

- Trizna Z, 87:127
 Tseleni-Balafouta S, 90:157
 Tukiainen E, 86:170
 Turc-Carel C, 89:175
 Tusell L, 89:163
 Tyrkus M, 89:177
 Tzeng C-H, 86:177
- U**
 Uchida H, 89:114
 Uchida T, 89:85
 Ueda R, 88:26
 Ueki K, 88:136
 Urbani CE, 87:88
 Urbini S, 88:95
 Utsumi S, 88:26, 89:166, 90:49
- V**
 Valgardsdóttir R, 92:37
 Vallcorba I, 92:79
 Vamos E, 89:77
 Vance CH, 92:111
 Van Damme B, 86:58, 87:85, 89:57
 van den Akker ThW, 86:156
 van den Berg E, 86:147, 92:141
 Van den Berghe H, 86:35, 86:39, 86:58, 86:86, 87:63, 87:79, 87:85, 87:176, 88:86, 89:57, 89:109, 89:181, 91:61, 91:106, 92:31, 92:147
 van de Pol M, 87:95, 89:146
 Van de Ven WJM, 86:39, 90:88, 91:1
 Van de Voorde W, 87:79
- van Drunen E, 90:109
 van Echten J, 87:95, 89:146
 Van Eyken P, 92:147
 Vanni R, 88:158
 Van Orshoven A, 86:35
 Van Poppel H, 87:79, 89:57
 Van Roy N, 90:86
 Varella-Garcia M, 86:46
 Varley JM, 90:14
 Vázquez-Mazariego Y, 92:79
 Vatcheva R, 87:103
 Vavourakis S, 86:65
 Vayego SA, 86:46
 Velloso ERP, 86:35
 Verellen-Dumoulin C, 88:86
 Vergot I, 91:61
 Verhest A, 86:174
 Verhoef G, 86:35, 88:86
 Verma RS, 88:167, 90:142
 Vig BK, 88:118, 91:101
 Viniou N, 91:82
 Virolainen M, 86:170
 Vissers KJ, 90:109
 Vogt N, 90:75
 Volkova MA, 87:182
 Volpi EV, 87:103
 von Deimling A, 88:136
 Vye MV, 86:29, 87:156
- W**
 Waggoner S, 89:93
 Wakasugi K, 89:114
 Waldman FM, 90:95
 Walker AM, 87:48
 Walker DA, 88:76
 Walter RB, 88:144
 Wang L, 89:184
- Wang X, 89:184
 Wanschura S, 86:39, 90:88
 Ware J, 87:14
 Watanabe A, 89:85
 Watkins D, 92:73
 Watts EJ, 87:48
 Webb HD, 88:126
 Weckermann D, 88:8
 Weh HJ, 87:52
 Wei C-H, 86:177
 Weier H-U, 90:37
 Weinstein R, 87:55
 Weismanová E, 91:88
 Werner M, 90:154
 Wessels HW, 89:132
 Wiernik PH, 86:31
 Wiersema J, 92:141
 Wiklund T, 86:170
 Wilkinson A, 88:76
 Willén R, 92:90
 Williams B, 91:77
 Winkler K, 88:103
 Wisecarver J, 91:65
 Wlodarska I, 86:35, 89:109
 Woessner S, 86:162
 Wong KF, 86:153, 88:80, 88:151
 Wu M, 89:184
 Wu X, 87:127
 Wyandt HE, 89:170
 Wymer J, 87:55
 Wysocka B, 92:85
- X**
 Xie J-X, 88:110
 Xie X, 92:18
 Xu C, 88:110
- Xue Y, 92:18
- Y**
 Yamagata N, 86:72
 Yan S, 89:184
 Yang J-M, 87:55
 Yaniv I, 87:161
 Yao M, 86:69
 Yataganas X, 86:65
 Yaw K, 88:17
 Yeger H, 92:58
 Yehuda O, 86:1, 89:1
 Yoh S, 91:40
 Yonescu R, 87:167
 Yoneyama S, 86:72
 Yoshida M, 90:45
 Yoshida MA, 86:69
 Young C, 89:157
 Yu I-T, 86:177
- Z**
 Zabarovsky E, 86:95
 Zaizov R, 87:161
 Zalcberg IQ, 92:92
 Zambrano N, 90:125
 Zámečníková A, 91:88
 Zeller W, 89:109
 Zemanová Z, 86:131, 88:141
 Zhang C, 89:184
 Zhang H, 86:22
 Zhang L, 92:135
 Zhou J-y, 89:120
 Zhu D, 89:184
 Zielenska M, 92:58
 Zitzelsberger H, 90:37
 Zomas A, 86:89
 Zoubek A, 87:161
 Zunino A, 88:95



Subject Index to CGC Volumes 86-92

ABL/BCR; see BCR/ABL

Acute erythroblastic leukemia (M6)

chromosome changes in, 86:124
in Moroccan patients, 86:124

Acute lymphoblastic leukemia (ALL)

chromosome changes in, 87:123; 88:57, 69; 92:111
chromosome 21 triplication and quadruplication, 92:43
congenital ALL, 88:103
congenital in twins, 89:177
der(6) revealed in T-ALL by FISH, 86:131
dichotomy of hyperdiploidy, 92:8
dic(9;20)(p11;q11) in ALL, 92:111
distribution of gained chromosomes, 92:8
Down syndrome, ALL and t(8;14), 88:92
FISH with repetitive probes in follow-up, 88:69
FISH studies in, 87:123; 88:69; 89:136; 141; 92:111, 135
genes affected in, 86:76
gene studies, 88:110
ider(9) in ALL, 89:109
immunology, cytomorphology and cytogenetics, 88:57
in children, 88:57; 92:43, 111, 135
inversion (14)(q11q32) in T-ALL, 88:76
i(14q) in childhood T-ALL, 92:92
MRD in ALL, 88:110; 89:141
MLL/ENL in ALL, 88:103
molecular studies in, 86:76; 88:110
PCR follow-up of MRD, 88:110
subtle 12p deletion, 89:136
t-cell-ALL, 86:131
twins (monozygotic) and, 89:177
t(1;5)(q23;q33) in B-ALL, 87:4
t(1;6)(q22;p21) in T-ALL, 86:131
t(2;3)(p12;q37), del(8)(q24) and t(14;18)(q32;q21) in All, 86:76
t(4;11)(q21;q23) in, 89:177
t(5;12)(q31;q24) in childhood ALL, 89:163
t(10;11)(p11-15;q13-23) in L1, 86:31
t(11;18;19)(q23;q22;p13.3) in ALL, 88:103
t(12;21)(p13;q22) shown with FISH, 89:136
+7 in marrow cells, 88:133
+8, +8 in All, 92:135
+15 in, 89:27
+15 in L1 type, 89:27

Acute megakaryocytic leukemia (M7)

diagnostic and clinical aspects, 92:50
t(15;17)(q24;q21) in, 92:50

Acute monocytic leukemia (M5)

basophilia in, 86:80
chromosome changes in, 86:124
dup(1) in M5b
FISH study in, 87:52; 88:26
in Moroccan patients, 86:124
MLL gene rearrangement in M5a, 88:26
molecular studies in, 87:52; 88:26
near-tetraploidy in, 86:107
t(1;19)(q23;p13) in M5, 87:52
t(3;3)(q21;q26) in M5a, 88:90
t(9;11;22)(p22;q23;q11) in M5a, 88:26
t(10;11)(p11-15;q13-23) in M5a, 86:31
47,XY, +X,t(2;10)(q21.1;q26.1) in M5b, 86:80

Acute myeloblastic leukemia (AML)

AML(M0) with i(18p), 92:1
AML1 and t(8;21) in, 88:151

AML1 gene rearrangement, 88:151

aplastic anemia prior to M0-AML, 92:1

BMT in, 86:1

chromosome changes in, 86:124; 88:69, 89:126, 92:18

complex translocation in, 86:8; 88:69

c-myc in M2 after MDS, 86:183

dup(10q) in, 89:1

eosinophilia and t(4;7) in AML(M2), 86:89

FISH and 5q-, 89:126

FISH in AML(M2), 86:89; 89:126; 91:40

FISH studies in, 89:126, 132; 91:40

FISH studies in follow-up, 88:69

idic(7)(p10) in M2, 89:132

in Moroccan patients, 86:124

MLL changes without 11q23 changes, 86:13

MLL in, 86:13

M2 in CLL, 87:38

near-hexaploid, 86:61

near-tetraploidy in M1, 86:107

partial +4 from t(4;7) in AML(M2), 86:89

Ph+ AML(M1), 86:61

tetraploidy and near-tetraploidy, 92:18

tetrasomy 8 in M2, 89:44

t(2;3)(p13q26) in M2, 87:182

t(3;3)(q21;q26) in M2, 87:11

t(8;21) and its variants studied with FISH, 91:40

t(8;21)(q22;q22) in, 86:8; 91:40; 92:18

t(12;15)*p13;q13 in M2 at relapse, 86:165

t(Y;1)(q12;q12) in, 86:35

with major BCR/ABL transcript, 86:61

5q- in, 89:126

+8, +8 in AML(M2), 89:44

+10 in AML(M0 and M1), 89:173

+10 in M0 and M2, 89:114

+13 in, 87:92

Acute myelogenous leukemia; also see Acute myeloblastic leukemia and Acute nonlymphocytic leukemia

t(5;21)(q13;q22) in, 86:167

with lymphoid surface antigens, 88:167

Acute myeloid leukemia; also see acute nonlymphocytic leukemia

dup(10q) in, 89:1

dup(10q) lacking α -satellite DNA, 89:1

Acute myelomonocytic leukemia (AMML; M4)

chromosome changes in, 86:124

in Moroccan patients, 86:124

near-tetraploidy in, 86:107

t(7;11)(p15;p15) in, 86:72

t(12;20)(q13;p11.2) in, 89:118

+11 in, 86:65

+13 in, 86:65

+15 in, 89:27

-Y in, 86:65

Acute nonlymphocytic leukemia (ANLL)

changes in AML(M2), 86:89

changes in M5b, 86:80

chromosome changes in, 86:65

FISH with repetitive probes in follow-up, 88:69

inv(3)(q21q26) in AML(M0), 88:90

multiple unrelated clones, 88:141

near-tetraploidy in, 86:107

tetrasomy 8 in M2, 89:44

- t(7;11)(p15;p15) in M4, 86:72
 t(12;20)(q13;p11.2) in M4, 89:118
 +8,+8 in AML(M2), 89:44
 IMA3111 and +13 in, 86:65
- Acute promyelocytic leukemia (APL)**
 t(15;17)(q22;q11) in, 86:8
 t(15;17)(q22;q12) in, 86:29
 t(15;17)(q22;q21) in, 86:86, 87:172; 91:40
 complex translocations in, 86:8
 therapy-related APL, 86:29
 extramedullary, 86:29
 in Klinefelter syndrome, 86:86
 RAR- α gene in, 87:172
 molecular studies in, 87:172
 t(16;17)(p24;q21) without RAR- α change, 87:172
 17q21 in APL, 87:172
 t(1;15;17)(p31;q21;q21) in APL, 89:52
 RAR α gene and PML gene in, 89:52
 FISH studies of t(1;15;17), 89:52
 t(15;17) variants studied with FISH, 91:40; 92:54
 FISH studies in, 91:40
 SCF, IL-6, IL-3 and GM-CSF in cultured cells, 91:77
 t(15;16;17;19) in, 92:54
 PML and RARA probes, 92:54
- Acute undifferentiated leukemia (AUL)**
 chromosome changes, 92:31
 clinicobiologic features, 92:31
 karyotypic changes, 92:31
 stem cell type, 92:31
 undifferentiated, 92:31
- Adenomas**
 breakpoints, 86:39
 chromosome 12 in pleomorphic, 86:39
 karyotypes in, 86:39
 lung, alveolar, 89:34
 pleomorphic, 86:39
 translocations in pleomorphic, 86:39
- Adrenocortical carcinoma**
 bilateral, 88:181
 LOH in, 88:181
 molecular studies in, 88:181
 p53 and RB genes in, 88:181
- Allelic loss**
 in renal cell cancer, 87:133; 88:66
 at 3p in RCC, 87:133
 of L-MYC in renal cell cancer, 88:66
 in prostate cancer, 90:37
- Alveolar adenoma of lung**
 FISH studies in, 89:34
 t(10;16)(q23;q24) in, 89:34
 unbalanced t(10;16) in, 89:34
- Ameloblastoma**
 del(10)(p12) in, 91:74
 -22 in, 91:74
- Amplification**
 of 19q13.1-q13.2 in ovarian cancer, 87:55
- Angiomyxoma**
 chromosome changes (table), 90:54
 in female, 89:61
 of soft parts, 89:61
 t(X;10)(q22;q23.2) in, 90:54
 -X in, 89:61
 12q14-15 and fusion product, 91:151
- Aplastic anemia**
 preceding AML-M0, 92:1
- Astrocytoma**
 anaplastic, 90:1
 aneuploidy in, 88:95
 cytogenetics, 90:1; 91:13
 in Klinefelter syndrome, 92:85
 molecular studies, 88:95
 p53 mutations in, 88:95
 telomeric association, 90:1
 17p12 in, 91:172
- Ataxia telangiectasia (AT)**
 breast cancer in, 92:130
 chromosome breakage, 87:112
 heterozygotes and breast cancer, 92:130
 lymphoblasts, 87:112
 molecular genotyping, 92:130
 topoisomerase II inhibition, 87:112
- Barrett's mucosa**
 cancer of the esophagus, 90:109
 cytogenetics of, 90:109
 in esophagus, 90:109
- Basal cell carcinoma**
 cytogenetics of, 91:177
 +6 in, 91:177
- BCR/ABL fusion**
 BCR/ABL gene, 89:166
 chimeric BCR/ABL gene, 89:166
 deletion of exon b3 of BCR, 91:71
 FISH studies of, 89:153, 157; 90:142
 in AML, 86:61
 in blood and marrow, 87:107
 in CML, 87:107; 89:153; 90:142
 in essential thrombocythemia, 89:74
 interphase FISH studies, 87:107
 major transcript, 86:61
 molecular demonstration of, 91:82
 molecular studies of, 86:61; 89:153; 91:71, 82
 variant, 89:153; 90:142
- Biphenotypic leukemia**
 t(2;6)(q31;q23) in, 91:104
- Bladder; see Urinary bladder**
- Blastic phase of CML**
 FISH studies in, 89:109
 ider(9) in CML, 89:109
 t(2;3)(p13;q26) in, 87:102
- Bloom syndrome**
 chromosome breakage, 87:112
 lymphoblasts, 87:112
 topoisomerase II inhibition, 87:112
- Bone**
 cyst, 86:46
 cytogenetics of cyst, 86:46
 giant cell tumor of, 88:35, 163
 unicameral cyst, 86:46
- Bone marrow**
 +7 in ALL marrows, 88:133
 +7 in normal marrows, 88:133
 +7 in precursor cells, 88:133
- Bone lesions and tumors**
 genetic instability, 91:157
 oncogene alterations, 91:157
 TP53 in, 91:156
- Bone marrow transplantation (BMT)**
 allogeneic, 86:1
 AML and BMT, 86:1
 cytogenetic analysis, 89:21
 FISH studies in, 89:141
 molecular studies in BMT, 86:1; 89:141
 residual disease in ALL, 89:141
 restriction endonuclease in situ digestion (REISD), 89:141
 -Y in donor cells after BMT, 86:1
- Brain tumors**
 aneuploidy in, 88:95
 astrocytomas, 88:95; 90:1
 chromosome 10, 91:173
 cytogenetics, 90:1; 91:173
 desmoplastic infantile ganglioglioma, 92:4
 FISH and cytogenetics, 91:173
 desmoplastic infantile ganglioglioma, 92:4
 FISH and cytogenetics, 91:173
 genes in tumors in *Drosophila*, 90:135
 glioblastoma, 87:41; 90:1

- in *Drosophila*, 90:135
- molecular studies in, 88:95
- p53 mutations, 88:95
- telomeric association in, 90:1
- Breast cancer**
 - acentric heterochromatin in cells, 88:118
 - anti-CENP antibodies in, 88:118
 - BRCA1 in families, 91:112
 - C-ERB-B₂ in, 86:18
 - cancer and normal tissue cytogenetics, 91:124
 - cell line, 88:118; 90:75
 - cell line and amplicon, 91:124
 - CGH analysis, 91:126
 - chromosome changes in families, 91:124
 - chromosome changes in fibroadenomas, 87:152
 - chromosomes 1, 3, 16 and 17, 88:1
 - correction of cytogenetics (63:47, 1992), 89:92
 - cytogenetics of, 91:128; 92:37
 - desmoid tumor and, 86:92
 - E-cadherin gene, 91:125, 128
 - fibroadenoma, 87:152
 - FISH and micrometastases in marrow, 88:8
 - FISH studies in, 88:1; 90:75; 91:126, 130
 - FISH studies of C-ERB-B₂ gene in, 86:18
 - gene amplification (C-ERB-B₂) in, 86:18
 - HER-2/*neu* in, 88:8
 - HSR(11) in cell line, 90:75
 - instability of chromosomes 1, 3, 16 and 17, 88:1
 - lymphocytes and chromosomal changes, 91:127
 - microsatellite changes, 91:131
 - molecular studies in, 86:18; 92:37
 - molecular vs cytogenetic analysis, 92:37
 - MUC1* gene in, 91:129
 - phyllodes tumor, 87:90
 - p53 in Brazil, 91:127
 - skeletal metastases and cytogenetics, 91:126
 - p53 changes, 91:129, 131
 - 3p- in, 91:125
 - +8 and +20 in, 86:92
 - 11q13 in, 91:130
- Bronchial cells**
 - cell lines, 92:99
 - chromosome changes in tumorigenesis, 92:99
 - epithelial, 92:99
- Canine thyroid adenoma**
 - karyotype, 90:156
 - +18 in, 90:154
- Cancer**
 - and supernumerary chromosome in family, 89:170
 - constitutive +8 and cancer, 86:87
 - familial, 90:125
 - heritable cancer syndrome, 90:125
 - karyotype, chromosome instability, 91:108
 - lung cancer, sex chromosome changes in patients, 87:24
 - p53 studies in, 90:125
 - +8 mosaicism, 86:87
- Cell lines**
 - alphoid sequences in acentric chromatin, 88:118
 - breast cancer line, 88:118
 - bronchial epithelium, 92:99
 - CCRF-CEM cell line, vincristine resistance and tubulin acetylation, 87:117
 - cervical, 90:63
 - clonal aspects of long-term lines, 90:91
 - colon cancer, 90:157
 - genes in malignant cell lines, 86:22
 - glioblastoma cell lines, 90:17
 - HL60 studies with FISH, 87:103
 - karyotypic evolution in CL52, 87:140
 - karyotypic features of HL60 cell line, 87:103
 - leukemia cell line (HL-60) and drug resistance, 86:116
 - liver (rat) cell line, 87:140
 - malignant, 86:22
 - molecular studies in malignant, 86:22
 - osteosarcoma, 91:1
 - prostate cancer (P69SV40T), 87:14
 - rat cell line CL52, 87:140
 - renal cell carcinoma, 86:95
 - testicular germ cell tumors, 87:95
 - thyroid cancer (PTC-1113A), 89:14
- Central nervous system (CNS) tumors; also see Brain tumors**
 - astrocytoma, 91:13
 - cytogenetics, 91:13
 - desmoplastic infantile ganglioglioma, 92:4
 - embryonal carcinoma, 91:13
 - ependymoma, 91:13
 - FISH study in, 91:13
 - glioblastoma, 91:13
 - medulloblastoma, 91:13
 - mutational screening, 91:174
 - NF2 gene in, 91:174
- Centromere(s)**
 - anti-centromere proteins, 91:101
 - FISH studies, 91:101
 - in mouse chromosomes, 91:101
 - lack of recognition, 91:101
- Cervical cancer**
 - cell cycle progression, 88:30
 - cell lines, 91:28
 - chromosome instability, 86:54
 - cytogenetics, 91:28
 - FISH studies, 91:28
 - genomic fragility, 88:30
 - HPV in cancer, 88:175
 - invasive carcinoma, 88:175
 - lymphocytes of patients, 88:30
 - molecular studies, 91:28
 - papilloma virus in cancer, 88:175
 - SCE in patients with, 86:54
- Cervix uteri carcinoma; see Cervical cancer**
 - cell lines, 90:63
 - papilloma virus, 90:63
 - virus integration sites, 90:63
- Chondroid hamartomas**
 - cytogenetic changes, 91:169
 - pulmonary, 91:169
- Chondrosarcoma**
 - CGH in, 91:164
 - cytogenetics of, 86:170; 89:49
 - dedifferentiated, 89:49
 - DNA copy number changes, 91:164
 - extraskelatal, 96:170
 - mesenchymal, 86:170
 - t(10;22)(p11.2;q11.2) in, 89:49
- Choriocarcinoma**
 - in Klinefelter syndrome, 92:85
- Choroid plexus carcinoma**
 - endoreduplication in, 87:7
 - telomeric association, 87:7
- Choroid plexus papilloma**
 - hyperdiploidy in, 90:130
 - karyotype in, 90:130
- Chromatid breaks**
 - mutagen sensitivity, 87:127
 - nomenclature systems, 87:127
 - type of breaks, 87:127
- Chromosome**
 - changes, aging, digestive tract, 91:166
 - chromosome 2 in endometriosis, 86:174
 - instability in patients with cervical cancer, 86:54
 - 1, 3, 16 and 17 instability in breast cancer, 88:1
 - 1p in hepatocellular carcinoma, 86:102
 - 1p in pigmented villonodular synovitis, 90:80
 - 2q31-qter duplication in lymphoma, 90:102
 - 3q21 and 3q26 in AML, 88:90
 - 7q in chronic lymphoid disorders, 92:24

- 7q21 and drug resistance, 86:116
 9p21 and genes at that region, 86:22
 11q23 and MLL in AML, 86:13
 12 in lipomas and adenomas, 86:39
 16q24 in nodular synovitis, 87:85
 19q13.1-q13.2 amplification in ovarian cancer, 87:55
 21 in ALL, 92:43
- Chromosome breakage; also see Chromatid breaks**
 syndromes, 87:112
 topoisomerase II inhibition, 87:112
- Chromosome changes**
 in adenomas (pleomorphic), 86:39
 in ALL, 86:76; 87:4, 123; 88:57, 69, 103
 in AML(M2), 86:89, 165; 87:11, 38; 88:69; 91:40; 92:18
 in ANLL, 86:107, 124, 165; 87:52; 88:69; 89:126
 in APL, 91:40
 in AUL, 92:31
 in bilateral renal tumors, 89:57
 in bone cyst, 86:46
 in brain tumors, 90:1 91:13
 in breast fibroadenomas, 86:152
 in cervical cancer cell lines, 91:28
 in chondrosarcoma, 86:170
 in choroid plexus cancer, 87:7
 in chromophobe RCC, 86:69
 in chronic lymphoproliferative disorders, 92:24
 in CLL changing to ALL, 86:143
 in CNS tumors, 91:13
 in colon cancer cell lines, 90:157
 in endometrioid ovarian cancer, 87:167
 in esophageal cancer, 90:109
 in Ewing tumor, 87:161
 in fibroma and related tumors, 87:34
 in germ cell tumors of testis, 87:95; 89:146; 91:95
 in glioblastoma, 87:41; 90:1
 in hepatocellular carcinoma, 88:170
 in lipomas, 86:39
 in lung cancer, 91:53
 in MDS, 88:86; 89:126
 in Merkel cell tumors, 92:79
 in mesodermal tumor of ovary, 88:53
 in mouse plasma cell diseases, 86:156
 in multiple myeloma, 86:162; 88:69; 90:171
 in myeloid leukemias, 86:153
 in M4, 86:72, 177
 in M5b, 86:80, 107; 87:48
 in osteosarcoma, 90:57
 in ovarian tumors, 92:95
 in peripheral nerve sheath tumors, 88:17
 in prostate cancer, 88:126; 90:37
 in prostate cancer cell line, 87:14
 in PV, 88:86
 in PVNS, 90:80
 in renal cell cancer, 86:95; 87:133
 in salivary gland cancer, 87:29
 in schwannoma, 88:17
- Chronic granulocytic leukemia; see Chronic myeloid leukemia (CML)**
- Chronic lymphocytic leukemia (CLL)**
 clonal evolution in ALL, 86:143
 chromosome changes in, 86:143; 92:24
 L3 type ALL in CLL, 86:143
 karyotypic evolution, 86:143
 M2 in CLL, 87:38
 FISH studies, 90:118
 +12 in, 90:118
 p53 deletion in, 90:118
 clinical correlations, 90:118
 molecular studies in, 90:118
- Chronic lymphoproliferative disorders (CLD)**
 chromosome changes, 92:24
 CLL, 92:24
 DLCL, 92:24
- FCCL, 92:24
 HCLV, 92:24
 MCL, 92:24
 NHL, 92:24
 PLL, 92:24
 SLVL, 92:24
 translocations in, 92:24
 7q anomalies, 92:24
- Chronic myelocytic leukemia; see Chronic myeloid leukemia (CML)**
- Chronic myelogenous leukemia; see Chronic myeloid leukemia (CML)**
- Chronic myeloid leukemia (CML)**
 BCR-ABL in interphase, 87:107
 BCR/ABL in Ph-negative CML, 89:166
 complex translocations in, 86:8; 89:153, 157; 90:142
 del(7)Pp11p15 in, 91:88
 duplication of 9q+ in Ph- CML, 89:166
 FISH analysis of BCR/ABL, 89:166; 90:142, 166
 FISH studies of interphase, 87:10
 granulocytes and chromosome 17 in CML, 90:156
 iger(9) in blastic phase, 89:109
 incidence of translocations vs that in lymphoma, 86:8
 i(17q) in, 90:166
 molecular studies in, 87:75; 89:157; 91:71
 normal chromosomes 17 in granulocytes, 90:166
 Ph-negative, 89:166
 pseudo-Pelger anomaly in Ph+ CML, 90:166
 t(2;3)(p13;q26) in blastic phase, 87:182
 t(4;9;22)(p16;q34;q11) in, 90:142
 t(9;22)(q34;q11) in, 86:8
 t(Y;22)(p11;q11) in, 87:75
 variant Ph, 87:75; 89:153, 157
 +21 in blast phase, 86:177
- Chronic myelomonocytic leukemia (CMML); see Myelodysplastic syndromes (MDS)**
- Clear cell sarcoma**
 malignant melanoma and, 91:37
 of aponeuroses, 91:37
 of tendons, 91:37
 t(12;22)(q13;q12) in, 91:37
- Cockayne syndrome**
 chromosome breakage, 87:112
 lymphoblasts, 87:112
 topoisomerase II inhibition, 87:112
- Colon tumors; also see Colorectal tumors**
 cytogenetics of polyps, adenomas and cancers, 91:120
 DCC gene in, 91:121
 hereditary nonpolyposis cancer, 91:107
 MSH2 and MLH1 genes, 91:121
- Colorectal tumors**
 cell line (cancer), 90:157
 cell senescence in, 90:157
 chromosome changes, 90:146, 157
 clonal accumulation, 92:11
 clonal evolution, 90:157
 colon cancer cell lines, 90:157
 DNA ploidy analysis, 90:146
 experimental model, 91:123
 FISH studies in, 90:146
 LOH in, 90:157
 marker chromosomes, 90:157
 p53 mutations, 91:122
 tumor heterogeneity, 90:157
 unstable rearrangements, 92:11
 1p- in adenomas, 91:122
- Comparative genomic hybridization (CGH)**
 in testicular germ cell tumors, 87:95
 i(12p) and chromosome 12 studies, 87:95
 mesoblastic gains and losses, 89:7
 of archival tissues, 90:95
 of uveal melanomas, 90:95
 studies in mesothelioma, 89:7

- testicular germ cell tumors, 89:146
 12p- amplicon in germ cell tumors, 89:146
- Congenital mesoblastic nephroma**
 t(14;15)(q11;q24) in, 88:39
- Constitutional chromosome changes**
 autosomal trisomy and tumors, 87:63
 FISH study of t(1;22), 86:150
 tumors in, 87:63
 t(1;22)(p22;q11.2) and ependymoma, 86:150
 +8 mosaicism and cancer, 86:87
- Cytogenetic changes**
 in adenomas (pleomorphic), 86:39
 in ALL, 86:76; 87:4, 123; 88:57, 69, 103
 En AML(M2), 86:89, 165, 87:11, 38; 88:69; 91:40; 92:18
 in ANLL, 86:107, 124, 165; 87:52; 88:69; 89:126
 in APL, 91:40
 in AUL, 92:31
 in bilateral renal tumors, 89:57
 in bone cyst, 86:46
 in brain tumors, 90:1; 91:13
 in breast fibroadenomas, 86:152
 in cervical cancer cell lines, 91:28
 in chondrosarcoma, 86:170
 in choroid plexus cancer, 87:7
 in chromophobe RCC, 86:69
 in chronic lymphoproliferative disorders, 92:24
 in CLL changing to ALL, 86:143
 in CNS tumors, 91:13
 in colon cancer cell lines, 90:157
 in endometrioid ovarian cancer, 87:167
 in esophageal cancer, 90:109
 in Ewing tumor, 87:161
 in fibroma and related tumors, 87:34
 in germ cell tumors of testis, 87:95; 89:146; 91:95
 in glioblastoma, 87:41; 90:1
 in hepatocellular carcinoma, 88:170
 in lipomas, 86:39
 in lung cancer, 91:53
 in MDS, 88:86; 89:126
 in Merkel cell tumors, 92:79
 in mesodermal tumor of ovary, 88:53
 in mouse plasma cell diseases, 86:156
 in multiple myeloma, 86:612; 88:69; 90:171
 in myeloid leukemias, 86:153
 in M4, 86:72, 177
 in M5b, 86:80, 107; 87:48
 in osteosarcoma, 90:57
 in ovarian tumors, 92:95
 in peripheral nerve sheath tumors, 88:17
 in prostate cancer, 88:126; 90:37
 in prostate cancer cell line, 87:14
 in PV, 88:86
 in PVNS, 90:80
 in renal cell cancer, 86:95; 87:133
 in salivary gland cancer, 87:29
 in schwannoma, 88:17
- Deletions**
 del(1)(q12) in prostate cancer, 87:79
 del(7)(p11p15) in CML, 91:88
 del(8)(q24) in ALL, 86:76
 del(9)(q22q34) in AML(M2), 86:89
 del(10)(p12) in ameloblastoma, 91:74
 del(20q) in hypereosinophilic syndrome, 87:82
 in adenomas, 86:40
 in prostate cancer, 88:126
 3p in renal cell cancer, 87:133
- Derivative chromosomes**
 der(3) in CLL, 86:143
 der(6) in T-ALL, 86:131
 der(16)t(1;16) in Ewing tumor, 87:161
 der(y) in PV transition to MDS, 88:83
 ider(9)(q10)t(9;22)(q34;q11) in ALL and CML, 89:109
 in adenomas, 86:40
 in prostate cancer, 88:126
 in testicular tumors, 87:97
- Dermatofibrosarcoma protuberans**
 ring chromosome in, 89:88
 t(17;22)(q21;q13), 91:151
 t(17;22)(q22;q13) in infant, 89:175
 17q and chromosome 22, 89:88
- Desmoid tumors**
 and breast cancer, 86:92
 chromosome changes, 92:147, 150
 FISH studies in, 92:147, 150
 5q- in, 92:150
 +8 and +20 in, 86:92; 92:147
 +8 in, 91:151
- Desmoplastic infantile ganglioglioma**
 chromosome changes, 92:4
 telomere association, 92:4
- Dicentric chromosomes**
 dic(1;15) in myeloid disorders, 88:86
 dic(1;15) in RA, 88:96
 dic(1;15) in PV, 88:86
 dic(9;20)(p11;q11) in ALL, 92:111
- Digital Image Analysis**
 analysis of C-ERB-B₂ gene, 86:19
 C-ERB-B₂ gene in breast cancer, 86:19
- Double minutes (dmin)**
 in osteosarcoma, 90:57
 in papillary thyroid cancer, 90:70
- Down syndrome**
 ALL with t(8;14)(q11;q32), 88:92
- Drosophila**
 brain tumors, 90:135
 mutant genes in brain tumors, 90:135
- Drug resistance**
 in leukemia cell line, 86:116
 to doxorubicin, 86:116
 7q21 anomalies and, 86:116
- Duplication**
 dup(1)(p22p36) in M5b, 87:48
 dup(10q) in AML, 89:1
 dup(10q) lacking α -satellite DNA, 89:1
 of chromosome 9 carrying BCR/ABL gene, 89:166
 of del(20)(q11) in MDS, 86:185
 2q31-qter in lymphoma, 90:102
- Embryonal carcinoma**
 cytogenetics of, 91:13
 CNS, 91:13
- Endometrial tumors and polyps**
 chromosome 1 in cancer, 91:137
 chromosomes 2 and 12, 90:88
 cytogenetic changes in, 90:88
 FISH study in, 90:88
 HMG-C rearrangement, 90:88
- Endomyometriosis**
 chromosome 2 in, 86:174
- Endoreduplication**
 in choroid plexus cancer, 87:7
- End-stage kidney**
 cytogenetic findings, 89:65
 functional transplant, 89:65
 molecular studies in, 89:65
 renal cell carcinoma in, 89:65
- Ependymoma**
 cytogenetics of, 91:13
 FISH studies, 86:150
 in patient with constitutional t(1;22)(p22;q11.2), 86:150
- Epithelioid hemangioendothelioma**
 complex t(7;22), 92:116
 chromosome changes, 92:116
- Epithelioid sarcoma**
 cytogenetics, 91:46
 FISH studies in, 91:46
 18q changes in, 91:46

Esophageal cancer

- Barrett's mucosa, 90:109
- cardia cancer, 90:109
- C-MYC gene in, 89:184
- cytogenetics of, 90:109
- in China, 89:184
- MDM2 gene in, 89:184
- molecular studies, 89:184
- no amplification of MDM2 and C-MYC in, 89:184

Ewing tumor or sarcoma

- der(16)t(1;16) in, 87:161
- EWS/ERG rearrangement, 87:161
- EWS/FLI-1 in, 91:162
- FISH studies, 91:162
- metastatic, 87:161
- molecular studies in, 87:161; 91:111
- neural histogenesis of sarcoma, 91:160
- p53, 91:161
- sarcoma, 90:176
- tetrasomy 8 and growth of marrow cell, 90:176
- variant translocation, 91:163
- +8 and +12 in, 91:163

Familial cancer and tumors

- adenomatous polyposis, 90:125
- cytogenetics of chordoma, 91:152
- deletion of TP53, 90:14
- germline mutations in, 90:125
- HNPCC in Lombardy, 91:114
- LOH of TP53 in benign lesion, 90:14
- melanoma, 91:116
- molecular studies, 90:14
- predisposition, 91:107
- p53 changes in, 90:125

Fanconi anemia

- cytogenetics in AML, 90:182
- in 22-yr-old male, 90:182

Fibroblasts

- cell line from retinoblastoma patients, 88:43
- cytogenetic response to irradiation, 88:43
- X-irradiation of cell from retinoblastoma patients, 88:43

Fibroma

- cardiac, 87:34
- fibroadenoma of breast, 87:152
- infantile, 87:34
- t(1;9)(q32;q22) in, 87:34

Fibrosarcoma

- chromosome changes in, 87:176
- multiple rearrangements in, 87:176

Fibrous tissue

- benign tumors, 87:34
- cytogenetics of tumors, 87:34

Fifth European Workshop on Cytogenetics and Molecular Genetics of Solid Tumors

- abstracts, 91:107-187
- introduction, 91:106

FISH species

- new linkage group and TP53, 88:144
- p53 orthologue in new linkage group, 88:144
- +p53 locus in *Xiphophorus*, 88:144

Fluorescence-in-situ hybridization (FISH)

- C-ERB-B₂ in breast cancer, 86:18
- chromosome-specific DNA probes, 89:120
- der(6) revealed by FISH in T-ALL, 86:131
- detection of i(12p) in germ cell tumors, 87:95
- dup(10q) in AML, 89:1
- FISH in AML(M2), 86:89; 88:69
- FISH in APL with t(15;17) and t(6;17), 87:172
- FISH in astrocytomas, 88:95
- FISH in follow-up of leukemias, 88:69
- FISH in glioblastoma, 87:41
- FISH in M5, 87:52
- FISH in ovarian cancer, 87:55
- FISH in parotid gland tumor, 89:38

- FISH in prostate cancer cell line, 87:14
- FISH in prostate cancers, 90:37
- FISH of BCR/ABL in Ph-CML, 89:166
- FISH of MLL/ENL fusion in ALL, 88:103
- FISH of t(11;18;19) in ALL, 89:103
- FISH studies in ALL, 87:123; 88:69
- FISH studies in CLL, 90:118
- FISH studies in colorectal tumors, 90:146
- FISH studies in Ewing tumor, 87:161
- FISH studies in fibrous tumor, 86:58
- FISH studies in leiomyoma, 89:98
- FISH studies in micrometastases in marrow, 88:8
- FISH studies in PNST, 88:17
- FISH studies in testicular tumors, 87:95
- FISH studies in thrombocytosis, 92:14
- FISH studies of BCR-ABL in CML, 87:107
- FISH studies of HL60 cell line, 87:103
- FISH studies of telomere, 89:31
- FISH study in ALL, 89:136
- FISH study in breast cancer cell line, 90:75
- FISH study in lung cancer, 89:120
- FISH study in Ph+ CML, 90:166
- FISH study of constitutional t(1;22), 86:150
- FISH study of ider(9)(q10), 89:109
- FISH study of tetrasomy 8, 89:44
- FISH study of t(1;15;17) in APL, 89:53
- FISH study of t(10;16) in lung adenoma, 89:34
- FISH study of +10 in AML, 89:114
- in breast cancer, 86:18; 88:1
- in gastric carcinoma, 91:122
- in inversion t(14) in ALL, 88:76
- interphase studies in CML, 87:107
- of tetrasomy 8 in ALL, 92:135
- painting probes, 89:126
- PCR of mRNA, 92:58
- quantitation of C-ERB-B₂ expression, 86:18
- repetitive probes in leukemias, 88:69
- rhabdomyosarcoma, 92:58
- selection of probes, 92:58
- studies in AML, 89:126; 132
- studies in ANLL, 91:40
- studies in APL with t(15;16;17;19), 92:54
- studies in cervical cancer cell lines, 91:28
- studies in MDS, 89:126
- studies of complex t(8;21) and t(15;17), 91:40
- study in osteosarcoma cell line, 91:1
- study of dic(9;20), 92:111
- study of idic(7)(p10), 89:132
- study of subtle 12p, 89:136
- study of variant Ph in CML, 89:153, 157
- study of 5q-, 89:126
- study of +7 in marrow, 88:133
- t(Y;1)(q12;q12) in hematologic malignancies, 86:35
- Y in male urinary cells, 88:155
- +7 as possible precursor change, 88:133
- +7 in ALL marrows, 88:33

Fragile sites

- active and inactive genes?, 88:184
- common and rare, 88:184
- fra(3)(p14.2) in lung cancer patients, 89:82
- fra(3)(p14.2) in lymphocytes, 89:82
- normal expression of fra(3)(p14.2), 89:82

Gastric tumors and cancer

- FISH studies in, 91:118; 92:122
- genetic changes, 91:118; 119
- in child with 18p-, 91:117
- leiomyosarcoma, 90:184
- low-grade, 90:184
- microsatellite instability, 91:117
- numerical changes in, 91:122
- 6q- in, 91:118
- +14 in leiomyosarcoma, 90:184
- 18p- and, 91:117

Gene(s)

- AML1 in AML, 88:151
 APC gene in colon polyps and retinal lesions, 91:112
 APC gene in Portuguese families, 91:113
 at 9p21, 86:22
 BAX gene in glioma, 88:136
 BCL-6 in B-lymphoma, 90:49
 BCR, deletion of b3 exon, 91:71
 C-ERB-B₂ gene in breast cancer, 86:18
 C-MYC and MDM-2 in esophageal cancer, 89:184
 CHOP and TLS/FUS in phyllodes tumors, 87:90
 DNA repair gene G/T glycosylase, 91:167
 EWS/ERG in Ewing tumor, 87:161
 FISH analysis of C-ERB-B₂, 86:18
 fusion partners of HMGI-C gene, 91:150
 HER-2/*neu* in breast cancer, 88:8
 HER-2/*neu* in prostate cancer, 88:8
 HMGI-C gene, 91:149, 150
 HMGI-C gene in osteosarcoma, 91:1
 HMLH1 in gastric cancer, 91:114
 HSMH2 and MHLH1 in Italian HNPCC families, 91:113
 IGH gene and translocations, 86:8
 in ovarian cancer, 87:55
 INK4 gene in malignant cell lines, 86:22
 interferon genes, 86:22
 K-ras in patient with multiple tumors, 86:181
 LOH of TP53 in benign lesion in cancer family, 90:14
 L-MYC in renal cell cancer, 88:66
 MDM2, CDK4 and HMGI-C genes, 91:149
 methylthioadenosine phosphorylase gene, 86:22
 MLL gene in AML, 86:13
 MLL in M5b, 88:26
 MLL rearrangement in AML without 11q23 aberration, 86:13
 mutant genes in *Drosophila* brain tumors, 90:135
 mutation of K-ras, 86:181
 MYC, BCL2 and J_H genes in ALL, 86:76
 NF-2 gene in gliomas, 92:73
 NF2 suppressor gene, 91:110
 PCR analysis in ALL, 88:110
 PML and RARA genes, 92:54
 proto-RET in thyroid cancer cell line, 89:14
 p15, p16 and p18 genes in osteosarcoma, 86:136
 P16 in malignant cells, 86:22
 P53 and RB in adrenocortical carcinoma, 88:181
 p53 deletion in CLL, 90:188
 p53 in heritable cancer, 90:125
 p53 in mantle cell lymphoma, 86:120
 p53 mutations in astrocytoma, 88:95
 RAR α and PML genes in APL, 89:53
 RAR- α gene in APL, 87:172
 RET in thyroid cancer, 89:14
 TP53 deletion in cancer family, 90:14
 TP53 in fish, 88:144
 3PK gene, 91:186
 8p and tumor suppressor gene, 91:123
 19q13.3, BAX gene and glioma, 88:136

Genomic imprinting; see Imprinting**Genomic instability**

- mismatch recognition in, 91:109

Germ cell tumors; also see Testicular tumors and Ovarian tumors

- AML following mediastinal tumor, 91:175
 pediatric, 91:174
 1p36.3 in pediatric, 91:174

Giant cell tumor of bone

- chromosome changes, 88:163
 lack of microsatellite instability, 88:35
 molecular studies in, 88:35
 telomeric association, 88:163

Glioblastoma

- BAX gene at 19q13.3, 88:136
 BAX gene in, 88:136
 cell lines, 90:17

- cytogenetics, 90:1; 91:13
 FISH studies in, 87:41
 microdissection of DNA, 87:41
 molecular studies in, 87:41
 multiforme, 90:1; 91:13
 protein expression in, 87:41
 telomeric association, 90:1
 tumor viruses in, 90:17
 17q11;2 in, 87:41

Glioma

- BAX gene in, 88:136
 BAX not altered in, 88:136
 cell line, 91:172
 LOH of chromosome 22, 92:73
 molecular studies in, 92:73
 NF-1 in, 92:73
 pediatric, cytogenetics, 91:173
 19q13.3 and BAX gene, 88:136

Hamartoma

- cytogenetics, 91:169
 pulmonary, 91:169

Hemangiopericytoma

- chromosome changes, 91:153

Hepatoblastoma

- chromosome 20 and 2q, 91:65
 primary and metastatic, 91:65

Hepatocellular carcinoma

- complex karyotype in, 88:170
 cytogenetics of, 88:170
 karyotype in, 86:102
 metastatic fibrolamellar, 88:170
 primary human, 86:102
 table of cytogenetic changes in, 88:172
 1p in, 86:102

Hereditary disorders

- defects in nucleotide-excision repair, 91:108

Homogeneously staining regions (HSR)

- HSR(11) in breast cancer cell line, 90:75
 in lymphoma, 87:1

Hypereosinophilic syndrome

- del(20q) in, 87:82

Imprinting

- genomic, 89:69
 genomic aberrations in human neoplasia (table), 89:70
 in carcinogenesis, 89:69
 relaxation of, 89:69

Inversions

- FISH studies of, 88:76
 in childhood ALL, 88L76
 inv(14)(q11q32) in T-ALL, 88:76

Isochromosomes

- ider(9)(q10) in ALL and CML, 89:109
 idic(7)(p10) in AML, 89:132
 i(7q) in Wilms tumor, 86:168
 i(12p) in germ cell tumors, 87:95; 91:95
 i(12p) in testicular tumors, 87:95
 i(14q) in T-ALL, 92:92
 i(17q) in CML, 90:166
 i(17q) not present in granulocytes in Ph+ CML, 90:166
 i(18p) in AML-M0, 92:1
 use of FISH in i(12p) detection, 87:95

Karyotypic changes

- in adenomas (pleomorphic), 86:39
 in ALL, 87:76; 87:4, 123; 88:57, 69, 103
 in AML(M2), 86:89, 165; 87:11, 38; 88:69; 91:40; 92:18
 in ANLL, 86:107, 124, 165; 87:52; 88:69; 89:126
 in APL, 91:40
 in AUL, 92:31
 in bilateral renal tumors, 89:57
 in bone cyst, 86:46
 in brain tumors, 90:1; 91:13
 in breast fibroadenomas, 86:152
 in cervical cancer cell lines, 91:28

- in chondrosarcoma, 86:170
- in choroid plexus cancer, 87:7
- in chromophobe RCC, 86:69
- in chronic lymphoproliferative disorders, 92:24
- in CLL changing to ALL, 86:143
- in CNS tumors, 91:13
- in colon cancer cell lines, 90:157
- in endometrioid ovarian cancer, 87:167
- in esophageal cancer, 90:109
- in Ewing tumor, 87:161
- in fibroma and related tumors, 87:34
- in germ cell tumors of testis, 87:95; 89:146; 91:95
- in glioblastoma, 87:41; 90:1
- in hepatocellular carcinoma, 88:170
- in lipomas, 86:39
- in lung cancer, 91:53
- in MDS, 88:86; 89:126
- in Merkel cell tumors, 92:79
- in mesodermal tumor of ovary, 88:53
- in mouse plasma cell diseases, 86:156
- in multiple myeloma, 86:162; 88:69; 90:171
- in myeloid leukemias, 86:153
- in M4, 86:72, 177
- in M5b, 86:80, 107; 87:48
- in osteosarcoma, 90:57
- in ovarian tumors, 92:95
- in peripheral nerve sheath tumors, 88:17
- in prostate cancer, 88:126; 90:37
- in prostate cancer cell line, 87:14
- in PV, 88:86
- in PVNS, 90:80
- in renal cell cancer, 86:95; 87:133
- in salivary gland cancer, 87:29
- in schwannoma, 88:17
- Karyotypic evolution**
 - in liver cell line, 87:140
 - in rat cell line, 87:140
- Kidney tumor; see Renal cell carcinoma**
 - aberrant mammary tissue, 87:88
 - cell lines, 86:95
 - chromophobe, 86:69
 - congenital mesoblastic nephroma, 88:39
 - i(7q) in Wilms tumor, 86:168
 - oncocyoma, 92:28
 - polycystic disease, 87:88
 - Wilms tumor, 86:168
- Klinefelter syndrome**
 - APL in, 86:86
 - astrocytoma in, 92:85
 - choriocarcinoma in, 92:85
 - cytogenetics of tumors in, 89:77
 - neoplasia in, 92:85
 - retinoblastoma (hereditary) in, 89:77
 - rhabdomyosarcoma in, 89:77
 - teratoma, 92:85
 - t(15;17)(q22;q21) and APL in, 86:86
- Laryngeal cancer**
 - chromosome 9 in, 91:177
 - molecular study, 91:177
- Leiomyoma**
 - chromosome changes, 89:98
 - chromosome 6, 87:148
 - FISH studies in, 89:98; 91:137
 - HMG1 gene, 91:135, 136
 - of uterus, 87:148; 89:98
 - 7q- and cell lines, 91:136
- Leiomyosarcoma**
 - cytogenetics of, 91:153; 154
 - gastric leiomyosarcoma, 90:184
 - low grade and +14, 90:184
 - of uterus, 87:148
 - t(1;6)(p32-33;p21.3) in, 87:148
 - +14 as sole change, 90:184
- Li-Fraumeni syndrome; also see Familial cancer**
 - cytogenetics of rectal tumor in, 91:121
 - in 34 families, 91:115
 - intron 6 of TP53 in, 91:115
 - rectal tumor, 91:121
 - TP53 in, 91:115
- Lipoma**
 - breakpoints, 86:39
 - chromosome 12 in, 86:39; 91:48
 - FISH studies, 91:148
 - genetic analysis, 91:148
 - karyotypes in, 86:39
 - translocations, 86:39
- Liposarcoma**
 - chromosomes, 91:146; 92:141
 - discontinuity of 12q13-22 amplicon, 91:164
 - EWS and FUS/TLS genes, 91:147
 - EWS/CHOP fusion gene(s), 91:146, 147
 - FISH studies, 91:146
 - myxoid, 92:141
 - myxoid and non-myxoid, 91:146
 - t(12;16) in, 91:147
 - t(12;19;16)(q13;q13;p11.2) in myxoid, 92:141
 - with cartilaginous differentiation, 92:141
- Liver**
 - CGH and chromosome changes in hepatocellular cancer, 91:186
 - cytogenetics of sarcoma, 90:1
 - hepatoblastoma, 91:65, 186
 - polygenic model for cancer, 91:116
 - telomeric association in sarcoma, 90:1
 - undifferentiated embryonal sarcoma, 90:1
- Loss-of-heterozygosity (LOH)**
 - chromosome 22 in gliomas, 92:73
 - in glioma, 92:73
 - NF-2 gene and LOH of 22, 92:73
- Lung tumors and cancer**
 - alveolar adenoma, 89:34
 - aneuploidy in interphase nuclei, 89:120
 - cell cycle regulation in cancer, 91:165
 - chromosome 3, 91:166
 - chromosomes in non-small cell cancer, 91:53
 - cytogenetics of cancer, 91:53, 168
 - cytogenetics of cancer, 91:53, 168
 - FISH studies in, 89:120; 91:166
 - FRA3B deletion in carcinoma, 91:170
 - fra(3)(p14.2) in patients with lung cancer, 89:82
 - HOX genes in cancer, 91:167
 - LOH in small cell cancer, 91:170
 - non-small cell carcinoma, 89:120; 91:53, 168
 - sex chromosome abnormalities in cancer patients, 87:24
 - technique for chromosome analysis, 91:53
 - t(10;16) in an adenoma, 89:34
- Lymphoblasts**
 - chromosome breakage in, 87:112
 - in ataxia telangiectasia (AT), 87:112
 - in Bloom syndrome, 87:112
 - in chromosome instability syndromes, 87:112
 - in Cockayne syndrome, 87:112
 - in progeroid syndromes, 87:112
 - in Werner syndrome, 87:112
 - in xeroderma pigmentosum, 87:112
 - topoisomerase II inhibition, 87:112
- Lymphoma**
 - BCL-6 rearrangement, 90:49
 - childhood, 86:83
 - chromosome changes in early, 92:87
 - complex translocations in, 86:8
 - del(6q) in early, 92:87
 - FISH studies in lymphoma, 90:49, 102
 - follicular lymphoma and chromosomes 7 and 10, 89:129
 - HSR in, 87:1
 - IGH rearrangement and translocations, 86:8
 - mantle cell, 86:120

- molecular studies in, 90:49
- p53 mutation, 86:120
- somatic pairing of chromosomes 7 and 10, 89:129
- t(1;5)(q32;q35), CD30+ in anaplastic, 86:83
- t(3;14)(q27;q11) in B-lymphoma, 90:49
- t(8;14)(q24;q32) in, 86:8
- t(14;18)(q32;q21) in, 86:8
- 2q31-qter duplication, 90:102
- Lymphoid leukemias**
 - CLL changing to ALL, 86:143
 - complex translocations in, 86:8
 - translocations in, 86:8
- Malignant mixed mesodermal tumor**
 - of ovary, 88:53
 - cytogenetic findings, 88:53
- Malignant peripheral nerve sheath tumor**
 - cytogenetics, 91:8
 - NF-1 in, 91:8
- Malignant triton tumor**
 - cytogenetics, 91:8
 - NF-1 in, 91:8
- Mammary carcinoma; see Breast cancer**
- Mantle cell lymphoma**
 - leukemic, 86:120
 - p53 in, 86:120
- Mapping**
 - breakpoints on chromosome 12, 86:39
 - of breakpoints, 86:39
 - of CAG repeats to 3p24.2-22, 92:46
- Medulloblastoma**
 - cytogenetics, 91:13
 - FISH study in, 91:13
- Medulloepithelioma**
 - cytogenetics, 92:144
 - intraocular, 92:144
- Melanoma**
 - cell lines, 91:181
 - CGH of, 90:95
 - chromosomes 9 and 21 in cell lines, 91:181
 - chromosome 14 and murine melanoma, 92:66
 - chromosome 14 changes, 92:66
 - cytogenetics of ocular, 91:179; 180
 - molecular studies of murine, 92:66
 - molecular studies of uveal, 90:95; 91:180
 - MTS-1 gene in uveal, 91:180
 - murine, 91:66
 - ocular, 91:179
 - paraffin-embedded, 90:95
 - uveal, 90:95
- Meningioma**
 - CGH studies, 91:187
 - primary and recurrent, 91:187
- Merkel cell tumors**
 - cytogenetics, 92:79
 - neuroendocrine sarcoma, 92:79
- Mesenchymal tumors**
 - Ewing tumor, 87:161
 - giant cell tumor, 87:85
 - nodular tenosynovitis, 87:85
 - primitive, 87:71
 - t(4;19)(q35;q13.1) in, 87:71
- Mesothelioma**
 - benign, 92:90
 - CGH studies in, 89:7
 - gains and losses of DNA, 89:7
 - localized fibrous, 92:90
 - malignant, 89:7
 - t(2;3)(p21;p26) in benign, 92:90
- Methodologies**
 - chromosome analysis, IL-3 and IL-6, 90:171; 91:77
 - IL-3 and IL-6 in analysis of multiple myeloma, 90:171
 - image analysis for FISH, 91:182
 - in APL patients, 91:77
 - PCR products from paraffin embedded tissues, 91:182
 - SCF, IL-6, IL-3 and GM-CSF increase of mitotic index, 91:77
- Microdissection**
 - band-specific painting probes generated by, 89:126
 - of chromosomes in glioblastoma, 87:41
 - 5q- and FISH, 89:126
- Micronuclei**
 - amplified genes, 91:185
- Microsatellite instability**
 - in renal cell carcinoma, 86:69
- Minimal residual disease (MRD)**
 - gene markers, 88:110
 - in ALL, 88:110
 - multiple clone specific markers, 88:110
 - PCR follow-up in ALL, 88:110
- Mixed lineage leukemia**
 - childhood, 90:29
 - t(6;14)(q25;q32) in, 90:29
- Molecular studies**
 - AML1 in AML, 88:151
 - BAX gene in glioma, 88:136
 - BCR/ABL in thrombocytopenia, 89:74
 - C-ERB-B₂ gene in breast cancer, 86:18
 - C-MYC and MDM-2 in esophageal cancer, 89:184
 - C-myc in M2 after MDS, 86:183
 - CAG repeats at 3p24.2-22, 92:46
 - differential display PCR, 92:58
 - germline mutations in familial tumors, 90:125
 - in adrenocortical carcinoma, 88:181
 - in ALL, 86:76; 88:110
 - in ALL with t(11;18;19), 88:103
 - in ML, 86:61
 - in APL, 87:172
 - in API with PML and RARA probes, 92:54
 - in astrocytomas, 88:95
 - in BMT, 86:1
 - in breast cancer, 86:18
 - in breast cancer (micrometastases), 88:8
 - in breast cancer vs cytogenetics, 92:37
 - in cervical cell lines, 90:63
 - in CLL, 90:118
 - in CML and Ph, 87:75
 - in drug resistant leukemic cell line, 86:116
 - in end-stage kidney, 89:65
 - in esophageal cancer, 89:184
 - in essential thrombocytopenia, 89:74
 - in Ewing tumor, 87:161
 - in giant cell tumor of bone, 88:35
 - in glioblastoma, 87:41
 - in glioma, 92:73
 - in lipomas and adenomas, 86:39
 - in malignant cell lines, 86:22
 - in mantle cell lymphoma, 86:120
 - in marrow residual disease, 89:141
 - in M5, 87:52
 - in M5a (MLL), 88:26
 - in osteosarcoma, 86:136; 91:1
 - in ovarian cancer, 87:55
 - in phyllodes tumors of breast, 87:90
 - in prostate cancer, 90:37
 - in renal cell cancer cell lines, 86:95
 - in renal cell carcinoma, 87:133; 88:66; 89:65
 - in thyroid cancer cell line, 89:14
 - K-ras in patient with multiple tumors, 86:181
 - linkage and cytogenetic mapping of 3p24.2-22, 92:46
 - LOH in gliomas, 92:73
 - mitogenic signal transduction, 91:109
 - MLL changes in AML, 86:13
 - MLL changes without 11q23 aberration, 86:13
 - MRD and genes in ALL, 88:110
 - of BCR/ABL, 91:82
 - of BCR gene, 91:71
 - of interferon genes, 86:22

- of methylthioadenosine phosphorylase gene, 86:22
- of TP53 in fish, 88:144
- PCR of mRNA, 92:58
- probe selection, 92:58
- p15^{BK4} in malignant cells, 86:22
- p53 in cancer syndromes, 90:125
- REISD use, 89:141
- studies of p15 p16 and p18 genes in osteosarcoma, 86:136
- tools for, 91:187
- VNTR-sequence in solid tumors, 91:175
- Mouse diseases**
 - cytogenetic findings in, 86:156
 - multiple myeloma, 86:156
 - Waldenström macroglobulinemia, 86:156
- Multiple myeloma**
 - chromosome changes in, 86:162; 88:69; 90:171
 - cytogenetics of mouse, 86:156
 - FISH in follow-up, 88:69
 - IL-3 and IL-6 in chromosome analysis, 90:171
 - IL-3 and IL-6 improve cytogenetic analysis, 90:171
 - in mouse, 86:156
 - t(9;20)(p24;q11.2) in, 90:106
- Myelodysplastic syndrome(s) (MDS)**
 - age and karyotypic changes, 88:80
 - c-myc in M2 after MDS, 86:183
 - CMML and age, 88:80
 - cytogenetic changes, 89:126
 - der(y)t(Y;1)(q12;q12) in MDS after PV, 88:83
 - dic(1;15) in, 88:86
 - dup of del(20)(q11) in, 86:185
 - FISH in follow-up of RAEB, 88:69
 - FISH studies in, 89:126
 - karyotypic changes and age, 88:80
 - loss of telomeric sequences, 89:31
 - multiple unrelated clones in, 88:141
 - myelofibrosis and MDS, 90:24
 - refractory anemia with ringed sideroblasts (RARS) and age, 88:80
 - refractory anemia (RA) and age, 88:80
 - refractory anemia with excess blasts in transformation (RAEBT), 88:80
 - refractory anemia with excess blasts (RAEB) and age, 88:80
 - ring chromosome in, 89:31
 - t(Y;1)(q12;q12) in, 86:35
 - +13 in, 87:92
 - +15 in, 89:27
- Myelofibrosis**
 - acute, 90:24
 - karyotype in, 90:24
 - relation to MDS, 90:24
 - t(Y;1)(q12;q12) in, 86:35
- Myelofibrosis with myeloid metaplasia (MMM)**
 - karyotypes in, 87:156
 - polyclonality, 87:156
- Myeloproliferative disorders (MPD)**
 - BCR/ABL fusion in, 91:82
 - chromosome changes, 87:156; 91:82
 - dic(1;15) in PV, 88:86
 - myelofibrosis with myeloid metaplasia, 87:156
 - polyclonal changes in, 87:156
 - t(14;22)(q32;q11) in, 91:82
- Myeloid disorders (MPD)**
 - chromosome 3 in, 90:93
 - t(2;3) in, 90:93
- Nasal polyps**
 - atypical stromal cells in, 88:158
 - chromosome changes in, 88:158
 - extra copies of chromosomes, 90:86
 - polysomies in, 90:86
- Near-haploidy**
 - chromosome changes in, 92:28
 - in renal oncocyoma, 92:28
- Near-tetraploidy**
 - in adult AML, 86:107
- in AML, 86:107
- Neurilemoma**
 - cytogenetics, 90:1
 - telomeric association, 90:1
- Neuroblastoma**
 - cytogenetics of, 90:1
 - genetic alterations, 91:111
 - oncogene activation in, 91:171
 - telomeric association, 90:1
 - t(1;17)(p36;q11.2-12.1), 91:171
- Neuroendocrine carcinoma**
 - cytogenetics, 92:79
 - Merkel cells, 92:79
- Nodular tenosynovitis; see tenosynovial giant cell tumor**
- Non-Hodgkin lymphoma; see Lymphoma**
- Nonneoplastic tissues**
 - chromosome changes in, 88:158
 - nasal polyps, 88:158
- Obituary**
 - Mamaeva, Stella, 91:91
 - Thompson, Floyd, 88:186
- Oncocyoma**
 - chromosome changes, 89:57; 92:28
 - near-haploidy in, 92:28
 - renal, 89:57; 92:28
- Osteosarcoma**
 - cell line (OsA-CI), 91:1
 - chromosome changes in, 90:57; 91:158
 - cytogenetic anomalies in, 90:57
 - double minutes in, 90:57
 - FISH studies in, 91:1; 158
 - genetic instability, 91:157
 - HMGIC gene in, 91:1
 - karyotypes in, 90:57
 - molecular studies in, 86:136
 - monosomy 17p, 90:57
 - p15, p16 and p18 genes in, 86:136
 - xenografted, 90:57
- Ovarian tumors**
 - amplification of 19q13.1-q13.2 in, 87:55
 - borderline malignant, 92:95
 - carcinoma, 87:167
 - chromosome change in endometrioid cancer, 87:167
 - chromosome changes, 92:95
 - chromosome 6, 91:132; 133
 - chromosome 12 in fibrothecomas, 91:134
 - chromosome 12 in germ cell tumor, 91:61; 135
 - cytogenetics of malignant mixed mesodermal tumors, 88:53
 - FISH studies, 87:55
 - germ cell tumor, 91:61
 - granulosa cell tumors, 89:93
 - karyotypes in granulosa tumors (table), 89:96
 - malignant mixed mesodermal tumors, 88:53
 - mesodermal tumors, 88:53
 - molecular studies, 87:55
 - no i(12p) in germ cell tumor, 91:61
 - primary endometrioid carcinoma, 87:167
 - p21 in, 91:132
 - SCE in ovarian cancer patients, 89:105
 - 6q in, 91:132
 - +12 in +7 and r(1) in, 92:95
 - 22 in granulosa tumors, 89:93
- Pancreas**
 - chromosome 19 in cancer, 91:120
 - cytogenetics of cancer, 91:119
- Parotid gland; also see Salivary glands**
 - cytogenetics of cancer, 89:38
 - DNA ploidy in carcinoma, 89:38
 - FISH studies, 89:38
 - mucoepidermoid carcinoma, 89:38
 - t(3;12)(q24;p13) in cancer, 89:38
- Peripheral nerve sheath tumors**
 - chromosome changes in, 88:17

- cytogenetic and histologic correlation, 88:17
 FISH studies in, 88:17
 malignant (MPNST), 88:17
 of soft tissue, 88:17
 schwannoma: benign and malignant, 88:17
- Philadelphia (Ph) chromosome and translocations**
 complex translocations in CML, 86:8
 FISH study of, 90:142
 in acute leukemia, 92:92
 in AML, 96:61
 in CML, 86:8; 87:75
 interphase FISH studies, 87:107
 molecular studies of, 86:61; 87:75
 t(6;9;22)(p25;q34;q11) in acute leukemia, 92:82
 t(Y;22)(p11;q11) in CML, 87:75
 variant Ph, 87:75; 90:142
- Phyllodes tumor**
 CHOP and TLS/FUS genes in, 87:90
 molecular studies in, 87:90
 of breast, 87:90
- Pigmented villonodular synovitis (PVNS)**
 chromosome changes in, 90:80
 FISH study in, 90:80
 table of cytogenetic anomalies, 90:83
 1p changes in, 90:80
- Pituitary adenomas**
 cytogenetics, 91:183
- Plasma cell**
 cytogenetic changes in, 86:162
 diseases in mouse, 86:156
 multiple myeloma in mouse, 86:156
 Waldenström macroglobulinemia, 86:156
- Polycythemia vera (PV)**
 der(Y) in transition to MDS, 88:83
 dic(1;15) in, 88:86
 t(Y;1)(q12;q12) in, 86:35; 88:83
- Polymerase chain reaction (PCR)**
 differential display PCR, 92:58
 genes in ALL, 88:110
 in ALL, 88:110
 MRD follow-up, 88:110
 PCR of mRNA, 92:58
 study of BCR, 91:71
 two-round PCR, 91:71
- Prostate cancer**
 allelic imbalance, 91:145
 cell line (P69SV40T), 87:14
 chromosome changes in, 88:125; 90:37; 91:144
 chromosome changes in the differential diagnosis of a mass in
 leg, 86:147
 cytogenetic basis in metastasis, 86:147
 cytogenetic changes, 88:126; 90:37
 del(1)(q12) in, 87:79
 FISH studies in, 90:37; 91:144
 karyotype in metastasis, 86:147
 karyotypes in, 88:126; 90:37
 LOH in cancers, 90:37
 t(Y;22) in, 91:145
 uncultured prostate cancer, 88:126
- Rat**
 cell line (CL52), 87:140
 karyotypic evolution in cell line, 87:140
- Refractory anemia (RA); also see Myelodysplastic syndromes (MDS)**
 cytogenetic changes, 89:126
 FISH study in, 89:126
 5q- in, 89:126
 +15 in, 89:27
- Refractory anemia with excess blasts (RAEB); also see Myelodysplastic syndromes (MDS)**
 cytogenetic changes, 89:126
 FISH study in, 89:126
 5q- in, 89:126
- Refractory anemia with excess blasts in transformation (RAEBT); see Myelodysplastic syndromes (MDS)**
 in XYY males, 90:179
 loss of telomeric sequences, 89:31
 loss of telomeric sequences in ring, 89:31
 ring derived from chromosome 8, 89:31
- Renal cell carcinoma**
 allelic loss in, 87:133
 association with supernumerary nipple, 86:129
 bilateral, 91:142
 bilateral and synchronous, 89:57
 bilateral tumors in literature, 89:59
 cell lines, 86:95
 CGH studies, 91:140, 142
 chromophobe, 86:69
 chromophobe RCC, 91:138
 chromosomes in cell lines, 86:95
 cytogenetics of, 87:133; 89:57, 65; 91:140
 familial, 86:129
 FISH studies, 91:140
 genetic model, 91:141
 in end-stage kidney, 89:65
 L-MYC allelotype in, 88:66
 low chromosome number, 86:69
 microsatellite instability, 86:69
 molecular studies in, 87:133; 88:66; 89:65
 NM23 gene in, 91:140
 papillary vs nonpapillary, 87:133
 telomeres and telomerase, 91:139
 t(6;11)(p21;q13), 91:140
 t(X;1)(p11;q21) in, 91:138
 3p allelic loss in, 87:133
 3p21 and multiple tumors, 91:139
 3p21 and t(3;8), 91:142
 Wilms tumor, 91:142, 143
- Retinoblastoma**
 cytogenetics of, 88:77
 hereditary, 89:77
 in Klinefelter syndrome, 87:77
- Rhabdoid tumor**
 t(11;22)(q24;q12) in, 91:164
- Rhabdomyosarcoma**
 alveolar, 87:179
 der(16) as a secondary change, 87:179
 der(16)t(1;16)(q21;p13) in, 87:179
 FISH probes for, 92:58
 in Klinefelter syndrome, 89:77
 MYC-N and HSR, 91:159
 PAX-7/FKHR fusion gene, 91:159
 t(2;13) and translin, 91:160
 t(2;13)(q35;q14) in, 87:179
- Ring chromosome**
 derived from chromosome 8, 89:31
 FISH studies of, 89:88
 in dermatofibrosarcoma protuberans, 89:88
 in ovarian cancer, 92:95
 in RAEBT, 89:31
 loss of telomeric sequences, 89:31
 ring containing 17q and 22, 89:88
- Salivary gland**
 ameloblastoma of, 91:4
 carcinoma, 87:29
 cytogenetics of, 89:38
 del(10)(p12) in ameloblastoma, 91:74
 DNA ploidy analysis, 89:38
 FISH study in, 89:38
 LOH at 6q in malignant tumors, 91:168
 mucoepidermoid carcinoma, 89:38
 parotid, 89:38
 t(11;19)(q21;p13.1) in mucoepidermoid carcinoma, 87:29
 Warthin tumor cytogenetics, 91:169
 8q21 region mapping, 91:165
 -22 in ameloblastoma, 91:74

Sarcoma(s)

- cytogenetics, 90:1
- EWS/FLI1 gene fusion in, 91:161
- of liver, 90:1
- telomeric association, 90:1
- 1q21-22 amplicon, 91:156

Secondary leukemia

- cytogenetics, 87:38; 90:45
- in CLL, 87:38
- molecular studies in, 90:45
- 21q22 in, 90:45

Seminoma; see also testicular tumors

- CGH studies in, 89:146
- chromosome 12 changes in, 89:146
- cytogenetics of, 89:148

Sex chromosome anomalies

- table of hematologic malignancies in XYY males, 90:180
- XYY males and malignancy, 90:179

Sezary syndrome

- cytogenetic findings, 90:33
- FISH study in, 90:33
- immunophenotype, 90:33

Sister chromatid exchange (SCE)

- in lymphocytes, 89:105
- in ovarian cancer patients, 89:105
- in patients with cervical cancer, 86:54

Skin cancer

- chromosome breakpoints, 91:179
- molecular studies, 91:178
- p53 in, 91:178
- RAS gene in, 91:178

Soft tissue tumors

- CGH and chromosome anomalies, 91:156
- cytogenetics of borderline cases, 91:154
- p53 and gene amplification in sarcomas, 91:155

Solid tumors

- chromosome 3, 91:185, 186
- elimination test, 91:185
- heterochromatin of chromosomes 1, 9 and 16 in children, 91:176
- MYC-N and DDX-1 genes in, 91:176
- VNTR-sequences, 91:175
- 1p36 in, 91:175

Stomach tumors; see Gastric tumors**Supernumerary chromosome**

- and malignancy, 89:170
- cancer in family with, 89:170
- familial, 89:170

Synovial sarcoma

- of lung, 88:49
- SYT and SSX protein, 91:152
- t(X;18)(p11.2;q11.2) in, 88:49; 91:152

T-antigen

- BK and SV40 tumor viruses, 90:17
- coding sequences, 90:17
- in glioblastoma cell lines, 90:17
- of DNA tumor viruses, 90:17

T-cell acute lymphoblastic leukemia (ALL)

- ALL, 88:76
- childhood, 92:92
- der(6) revealed by FISH, 86:131
- extra Y in T-ALL, 89:85
- FISH studies in, 88:76
- inv(14)(q11;q32) in, 88:76
- i(14q) in T-ALL, 92:92
- t(1;6)(q22;p21) in, 86:131

Techniques; see Methodologies**Telomere**

- association in choroid plexus cancer, 87:7
- association in desmoplastic ganglioglioma, 92:4
- association in MPNST, 88:19
- association in pediatric tumors, 90:1
- chromosome 8 ring and loss of sequences, 89:31

- FISH studies of, 89:31
- integrity in tumors, 86:50
- loss of sequences, 89:31
- molecular studies of, 86:50
- tumor progression and association, 90:1

Teratoma

- in Klinefelter syndrome, 92:85

Testes, tumors; see Testicular tumors**Testicular tumors**

- CGH in, 87:95; 89:146
- chromosome 12 in, 87:95; 91:95
- cytogenetic changes in, 87:95; 89:146; 91:95
- FISH studies in, 87:95; 91:95
- germ cell tumors, 87:95; 89:146; 91:95
- i(12p) in, 87:95; 89:146; 91:95
- maternal loss of 1p in, 91:95
- pediatric, 91:95
- 12p-amplicon in, 89:146

Tetrasomy

- chromosome 8 tetrasomy, 89:44
- FISH study of, 89:44
- +8,+8 in AML(M2), 89:44
- +8,+8 in childhood ALL, 92:135

Therapy related leukemia; see Secondary leukemia**Thrombocythemia**

- BCR/ABL in essential, 89:74
- essential, 89:74; 91:68; 92:14
- FISH studies in, 92:14
- molecular studies in, 89:74
- t(13;14)(q32;q32.3) in, 91:68
- +8,+9 in, 92:14

Thrombocytosis; see thrombocythemia**Thymoma**

- in elderly female, 89:181
- t(15;22)(p11;q11) in, 89:181

Thyroid cancer and tumors

- anaplastic carcinoma, 91:184
- benign lesions, 91:194
- cell line, 89:14; 90:70
- chromosome analysis, 91:183, 184
- dmin in cell line, 90:70
- FISH studies, 91:184
- follicular carcinoma, 91:183
- molecular studies in, 91:109
- new cell line PPTC-1113A), 89:14; 90:70
- papillary cancer, 90:70; 91:109
- Proto-RET gene in, 89:14
- rearrangement of RET gene, 89:14

Translocations

- breakpoints in adenomas and lipomas, 86:39
- complex translocations, 86:8
- in adenomas (pleomorphic), 86:39
- in brain tumors, 90:1
- in chronic lymphoproliferative disorders, 92:24
- in fibromas and related tumors, 87:36
- in lipomas, 86:39
- in lymphoma and lymphoid leukemias, 86:8
- in myeloid diseases, 86:8
- in prostate cancer cell line, 87:14
- incidence in myeloid vs lymphoid states, 86:8
- translocations in brain tumors, 91:13
- translocations in cervical cancer cell lines, 91:28
- translocations in CNS tumors, 91:13
- translocations in osteosarcoma, 90:58
- t(1;1)(q32;q32) in multiple myeloma, 90:171
- t(1;2)(q10;p10) in testicular germ cell tumors, 89:148
- t(1;2)(q32;q23) in malignant mesodermal tumor of ovary, 88:53
- t(1;3)(q11;q27) in testicular germ cell tumors, 89:148
- t(1;5;13)(p13;q35;q14) in PVNS, 90:83
- t(1;5)(q23;q33) in ALL, 87:4
- t(1;5)(q32;q35) in lymphoma, 86:83
- t(1;6)((p32-33;p21.3) in leiomyosarcoma, 87:148
- t(1;6)(q22;p21) in T-ALL, 86:131

- t(1;6)(p23;p22) in AML of Fanconi anemia, 90:182
 t(1;6)(q25;p21.3) in breast fibroadenoma, 87:152
 t(1;7)(q22;q11.2) in MPNST, 88:19
 t(1;9)(a32;q22) in cardiac fibroma, 87:34
 t(1;12)(p31-32;q14) in lipoma, 86:40
 t(1;15)(p21;q23) in AML(M1), 88:69
 t(1;15;17)(p31;q23;q21) in APL, 89:52
 t(1;15)(q12;p11) in RA, 88:86
 t(1;15)(q12;q22) in bone cyst, 86:47
 t(1;16)(p11;q13) in multiple myeloma, 90:171
 t(1;16)(q12;q11.2) in Ewing tumor, 87:161
 t(1;16)(q21;q13) in rhabdomyosarcoma, 87:109
 t(1;17)(p12;q11.2) in schwannoma, 88:19
 t(1;17)(p36;q11.2-12.1) in neuroblastoma, 91:171
 t(1;19)(p11;p12) in PVNS, 90:83
 t(1;19)(q11;p13) in ALL, 88:57
 t(1;19)(q21;p13) in ALL, 87:123
 t(1;19)(q23;p13) in ALL, 88:57
 t(1;19)(q23;p13) in M5, 87:52
 t(1;20)(q21;q13) in chondrosarcoma, 86:170
 t(1;22)(p22;q11.2) constitutional in patient with ependymoma, 86:150
 t(2;3)(p12;q37) in ALL, 86:76
 t(2;3)(p13;q26) in M2 and blastic phase of CML, 87:182
 t(2;3)(p21;p26) in benign mesothelioma, 92:90
 t(2;3)(q14;p11) in renal cell cancer, 89:58
 t(2;4)(p23;q21) in PVNS, 90:83
 t(2;5)(q33;p13) in multiple myeloma, 90:171
 t(2;6;15)(q37;q21;q11) in MMM, 87:156
 t(2;10)(q21.1;q26.1) in M5b, 86:80
 t(2;10)(q32;q11) in ALL, 88:69
 t(2;12)(q35;q14) in lipoma, 86:40
 t(2;12)(q36;q14) in lipoma, 86:40
 t(2;13)(q35;q14) in rhabdomyosarcoma, 87:179
 t(2;16)(q33;q24) in pigmented villonodular synovitis, 87:87
 t(2;21;8)(p15;q22;q22) in AML(M2), 86:89
 t(2;21)(q21;q22) in secondary leukemia, 90:45
 t(2;22)(q33;q13) in nodular tenosynovitis, 87:87
 t(3;3)(q21;q26) in M2, 87:11
 t(3;3)(q21;q26) in thrombocytopenia with erythroid dysplasia, 87:11
 t(3;4)(p14;p15) in multiple myeloma, 90:171
 t(3;5)(p23;q12) in AML(M1), 88:69
 t(3;6)(p13;q25) in renal cell cancer, 89:59
 t(3;9;22)(p21;q34;q11) variant Ph, 89:154
 t(3;9)(p24;q12) in testicular germ cell tumors, 89:148
 t(3;9)(q13;p24) in testicular germ cell tumors, 89:148
 t(3;11)(p14;p15) in multiple myeloma, 90:171
 t(3;11)(q11;p15) in renal cell cancer, 89:58
 t(3;12)(q24;p13) in parotid gland cancer, 89:38
 t(3;12)(q28;q14-15) in lipoma, 86:40
 t(3;14)(q27;q11) in lymphoma, 90:49
 t(3;15)(p23;q24) in testicular germ cell tumors, 89:148
 t(3;15)(q13;q24) in PVNS, 90:83
 t(3;17)(p11;q12) in CLL, 86:143
 t(3;18)(p21;p11) in PVNS, 90:83
 t(4;5)(p16;q13) in breast fibroadenoma, 87:152
 t(4;7)(q27;q32) in AML(M2), 86:89
 t(4;8)(p16;q11) in malignant mesodermal tumor of ovary, 88:53
 t(4;9;22)(p16;q34;q11) in CML, 90:142
 t(4;9)(q23;q22) in chondrosarcoma, 86:170
 t(4;10)(q22;q26) in multiple myeloma, 90:171
 t(4;11)(q21;q23) in ALL, 87:123; 88:57
 t(4;11)(q21;q23) in twins with ALL, 89:177
 t(4;12)(p14;q12) in breast fibroadenoma, 87:152
 t(4;19)(q35;q13.1) in mesenchymal tumors, 87:71
 t(5;6)(p15;p11) in malignant mesodermal tumor of ovary, 88:53
 t(5;6)(q14;q24) in nodular tenosynovitis, 87:87
 t(5;12)(q31;q24) in childhood ALL, 89:163
 t(5;14)(q11;q24) in PVNS, 90:83
 t(5;17)(q21;q12) in RAEB, 88:69
 t(5;21)(q13;q22) in AML, 88:167
 t(6;9;22)(p24;q34;q11) in acute leukemia, 92:82
 t(6;12)(p22;q14) in adenoma, 86:40
 t(6;12)(p22.2;q12.2) in adenoma, 86:40
 t(6;14)(q21;q32) in breast fibroadenoma, 87:152
 t(6;14)(q25;q32) in mixed lineage leukemia, 90:29
 t(6;17)(p24;q21) in APL, 87:172
 t(6;21)(p11;p12) in testicular germ cell tumors, 89:148
 t(6;22)(p23;q13) in multiple myeloma, 90:171
 t(7;11)(p15;p15) in M4, 86:72
 t(7;12)(p15;q15) in adenoma, 86:40
 t(7;12)(q21;q12) in ALL, 88:57
 t(7;16)(q22;q24) in pigmented villonodular synovitis, 87:87; 90:83
 t(7;18;14)(q11;q12;q12) in AML(M1), 88:69
 t(7;22)(q11;p12) in testicular germ cell tumors, 89:148
 t(8;2;16;21)(q22;q32;q13;q22) in AML(M2), 88:69
 t(8;9)(q12 or 13;p22) in adenoma, 86:40
 t(8;12)(p11.2;p11.2) in testicular germ cell tumors, 89:148
 t(8;12)(q10;p11) in testicular germ cell tumors, 89:148
 t(8;14)(q11;q32) in ALL with Down syndrome, 88:92
 t(8;14)(q24;q11) in ALL, 88:57
 t(8;14)(q24;q32) in lymphoma, 86:8
 t(8;21) and its variants studied with FISH, 91:40
 t(8;21)(q22;q22) in AML, 86:8, 126; 88:151
 t(8;21)(q22;q22) in secondary leukemia, 90:45
 t(8;22)(q24;q11) in ALL after CLL, 86:143
 t(9;11)(p21;q23) in AML, 86:126
 t(9;11;11)(q13;q13;q25;q25) in testicular germ cell tumors, 89:148
 t(9;11;22)(p22;q23;q11) in AML-M5a, 88:26
 t(9;12;22)(q34;q15;q11) variant Ph, 89:154
 t(9;20)(p24;q11.2) in myeloma, 90:106
 t(9;22)(q34;q11) in ALL, 87:123
 t(9;22)(q34;q11) in AML, 86:61, 126
 t(9;22)(q34;q11) in CML, 86:8
 t(9;22;15;13;17)(q34;q11;q26;q24;q11) variant Ph, 89:157
 t(10;11)(p11-15;q13-23) in AML and ALL, 86:31
 t(10;16)(q23;q24) in alveolar lung adenoma, 89:34
 t(10;22)(p11.2;q11.2) in chondrosarcoma, 89:49
 t(11;14)(p14;q12) in ALL, 88:57
 t(11;14)(q13;q32) in CLL, 86:143
 t(11;14)(q13;q32) in multiple myeloma, 90:171
 t(11;17)(p15;q23) in AML(M2), 88:69
 t(11;17)(q23;q24) in AML(M1), 88:69
 t(11;18;19)(q23;q22;p13.3) in ALL (congenital), 88:103
 t(11;19)(q13;p13) in multiple myeloma, 90:171
 t(11;19)(q21;p13.1) in salivary gland cancer, 87:29
 t(11;22)(q24;q12) in rhabdoid tumor, 91:164
 t(12;12)(q14;q23) in lipoma, 86:40
 t(12;14)(p13;q22) in epithelioid sarcoma, 91:46
 t(12;14)(q15;q11.2 or 12) in adenoma, 86:40
 t(12;15)(p13;q13) in M2 at relapse, 86:165
 t(12;16)(q14;q23) in adenoma, 86:40
 t(12;16)(q21;q23) in lipoma, 86:40
 t(12;17)(p11;q11) in AUL, 92:31
 t(12;17)(q23;q22) in MMM, 87:156
 t(12;19;16)(q13;q13;p11.2) in myxoid liposarcoma, 92:141
 t(12;20)(p11;p11) in testicular germ cell tumor, 89:148
 t(12;20)(q13;p11.2) in M4, 89:118
 t(12;21)(p11;p11) in testicular germ cell tumor, 89:148
 t(12;21)(p13;q22) in ALL, 89:136
 t(12;22)(q13;q12) in clear cell sarcoma, 91:37
 t(13;14)(q32;q32.3) in thrombocytopenia, 91:69
 t(14;15)(q11;q24) in congenital mesoblastic nephroma, 88:39
 t(14;18)(q32;q21) in ALL, 86:76
 t(14;18)(q32;q21) in lymphoma, 86:8
 t(14;19)(q13;q13) in RAEB, 88:69
 t(14;20)(q11;p11) in testicular germ cell tumors, 89:148
 t(14;22)(q32;q11) in MPD, 91:82
 t(14;22)(q32;q11) variant Ph, 89:154
 t(15;15)(p13;q11) in testicular germ cell tumors, 89:148
 t(15;16;17;19) in APL, 92:54
 t(15;17) and its variants studied with FISH, 91:40
 t(15;17)(q22;q11) in APL, 86:8

- t(15;17)(q22;q21) in APL, 87:172
 t(15;17)(q22;q21) in APL in Klinefelter, 86:86
 t(15;17)(q24;q21) in ANLL-M7, 92:50
 t(15;21)(p11;q11) in bone cyst, 86:47
 t(15;22)(p11;q11) in thymoma, 89:181
 t(17;18)(q11;p11) in Sezary syndrome, 90:33
 t(17;22)(q22;q13) in dermatofibrosarcoma protuberans, 89:175
 t(18;22)(q11;p11.2) in epithelioid sarcoma, 91:46
 t(19;22)(p13;q13) in MMM, 87:156
 t(X;1)(q21;q12) in testicular germ cell tumor, 89:148
 t(X;10)(p10;p10) in myeloid leukemias, 86:153
 t(X;10)(q22;q23.2) in angiomyoma, 90:54
 t(X;12)(q23;q12) in testicular germ cell tumor, 89:148
 t(X;14)(q22;q11) in testicular germ cell tumor, 89:148
 t(X;18)(p11.2;q11.2) in synovial sarcoma, 88:49
 t(Y;1)(q12;q12) in hematologic malignancies, 86:35
 t(Y;1)(q12;q12) in PV transition to MDS, 88:83
 t(Y;22)(p11;q11) in CML with Ph, 87:75
- Trisomy**
 constitutional and tumors, 87:63
 FISH studies of +21, 86:58
 FISH study of +10, 89:114
 partial +4 in AML(M2), 86:89
 +7 in normal marrow, 88:133
 +7 in patients with ALL, 88:133
 +8 and +20 in desmoid tumor of breast, 86:92
 +8 mosaicism and cancer, 86:87
 +8, +20 in desmoid tumors, 92:147
 +10 in AML and ALL (table), 89:116
 +10 in AML (M0 and M1), 89:173
 +11 and +13 in M4, 86:65
 +12 and +7 in ovarian tumors, 92:95
 +13 in MDS and AML, 87:92
 +15 in blood disorders, 89:27
 +20 in urethral cancer, 90:132
 +21 in fibrous tumor, 86:58
 +21 in myeloid leukemias, 86:177
- Tumors**
 benign, genetic basis, 91:110
 cytogenetics, 91:110
 Ewing tumor, 87:161
 fibrous, 86:58
 in patients with constitutional trisomy, 87:63
 lung, 89:34
 mesenchymal, 87:71
 multiple and K-ras, 86:181
 pediatric, 90:1
 phyllodes tumor of breast, 87:90
 solid, 86:50
 telomere integrity, 86:50
 telomeric association in, 90:1
 testicular, 87:95
 Wilms tumor, 86:168
 +21 in solitary fibrous tumor, 86:58
- Twins**
 congenital ALL, 89:177
 monozygotic and ALL, 89:177
 t(4;11)(q21;q23) in congenital ALL, 89:177
- Tynosynovial giant cell tumor**
 translocations in, 87:85
 16q24 in, 87:85
- Ureter**
 papillary urothelial carcinoma, 90:132
 +20 in carcinoma, 90:132
- Urinary bladder**
 FISH studies, 91:143
 FISH studies of Y in urinary cells, 88:155
 9q- in, 91:143
 -Y in male urinary cells, 88:155
- Uterine cervix; see Cervical cancer**
- Uterus; see also Cervical cancer**
 chromosome 6 in, 87:148
 leiomyoma, 87:148
 leiomyosarcoma, 87:148
 molecular changes in cervix, 91:134
 smooth muscle tumors, 87:148
- Viruses**
 BK and SV40, 90:17
 in cervical cell lines, 90:63
 in glioblastoma cell lines, 90:17
 integration sites, 90:63
 papilloma virus, 90:63
 T-antigen of, 90:17
 tumor viruses, 90:17
- Waldenström macroglobulinemia**
 cytogenetic changes in mouse, 86:156
 in mouse, 86:156
- Werner syndrome**
 chromosome breakage, 87:112
 lymphoblasts, 87:112
 topoisomerase II inhibition, 87:112
- Wilms tumor**
 CGH, 91:142
 karyotyping, 91:143
 needle biopsy, 91:143
 i(7q) in adult, 86:168
- X chromosome**
 changes in lung cancer patients, 87:24
 -X in angiomyoma, 89:61
 +X in M5b, 86:80
- Xeroderma pigmentosum**
 chromosome breakage, 87:112
 fibroblast clones, 91:181
 lymphoblasts, 87:112
 topoisomerase II inhibition, 87:112
 unbalanced karyotypes, 91:181
- X-irradiation**
 cytogenetic response in fibroblasts, 88:43
 retinoblastoma fibroblasts, 88:43
- Y chromosome**
 changes in lung cancer patients, 87:24
 in male urinary cells, 88:155
 RAEB in XYY males, 90:179
 t(Y;1)(q12;q12) in hematologic malignancies, 86:35; 88:83
 XYY in malignancy (table), 90:180
 XYY males and hematologic malignancy, 90:179
 -Y in ALL, 88:59
 -Y in donor cells after BMT, 86:1
 -Y in M4, 86:65
 +Y in T-ALL, 89:85
 -Y in urinary cells, 88:155

